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ABSTRACT
G protein–coupled receptors (GPCRs) are seven transmembrane domain
cell surface proteins that respond to a variety of environmental cues.
Response of these receptors to their cognate stimuli on the extracellular
region of the cell results in a concurrent activation of a complex series of
intracellular signaling pathways that prepare the cell for the required
adjustments through regulation of gene expression levels.  Participation of
GPCRs in such intricate signal transduction pathways renders them important
players in human diseases.  The GPCR family of proteins therefore
represents one of the largest classes of proteins to be targeted in the
development of drug design for clinical applications.
In light of the crucial role that GPCRs play in clinically important
diseases, the focus of this dissertation has been on interactions between a
GPCR and its ligand in a model eukaryotic organism, the budding yeast
Saccharomyces cerevisiae.  Very recently, the complete genome of the yeast
S. cerevisiae has been sequenced.  Detailed studies in this system along with
the available sequence information have suggested a high conservation
between the two eukaryotic organisms human and yeast.  Therefore, the S.
cerevisiae GPCR Ste2p and its associated pheromone ligand a–factor
represent a good model system to study ligand–receptor interactions.
The work presented in this dissertation describes results from a
comprehensive mutagenesis approach on Ste2p aimed at determining
residues of the receptor that are important in ligand binding and/or
viii
receptor activation.  Regions of the receptor that have been the primary
focus of the studies detailed in this dissertation are the first and third
extracellular loops of Ste2p.  Additional focus has been given to specific
residues located in the transmembrane regions of Ste2p that have been
predicted to interact with one another.
Cys–scanning and Ala–scanning mutagenesis studies on the first
extracellular loop, EL1, of Ste2p resulted in identification of a region of this
loop harboring five functionally important residues that played an important
role in the activation of the receptor but did not contribute to ligand
binding.  Structural studies on EL1 pointed to the possibility that this region
of EL1 may attain a 310–helical structure in which the five functionally
important residues may lie on one face of this helix.  Collectively, all these
studies underscored the important role of EL1 in Ste2p activation.
Structure and function studies on the third extracellular loop, EL3, of
Ste2p, using a Cys–scanning mutagenesis approach led to the identification
of two additional residues that, upon mutation, resulted in a defective
receptor.  These results indicated the important role that EL3 played in the
activation of the receptor–mediated signal transduction pathway.
Scanning mutagenesis studies on EL1 and EL3 emphasized the
importance of these loop residues in receptor structure and function.  As a
result, signal–deficient mutants from EL1 and EL3 were studied further to
assess their functional properties after combining individual mutations
rendering Ste2p defective with a constitutively activating mutation.  These
studies allowed identification of mutant receptors with intermediate
signaling properties and intermediate conformations.  Results from these
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studies, once again, underlined the importance of EL1 and EL3 residues in
the activation of Ste2p, and further suggested that the activation
mechanism for Ste2p followed multiple intermediate conformations.
In addition to studies with the extracellular loops of Ste2p, certain
residues in the transmembrane regions of the receptor became focus of this
dissertation.  De novo models, generated in collaboration with Dr.
Nikiforovich of Washington University (St. Louis, MO), for the
transmembrane regions of Ste2p proposed specific contact sites in the
three–dimensional structure of Ste2p.  These residues were targeted by a
strategically designed mutagenesis approach to test the validity of the de
novo models.  Results from these studies partially corroborated predictions
of these first de novo models, and provided a framework in which to
incorporate the connecting loops to obtain the complete three–dimensional
model for Ste2p.
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1PART I.  GENERAL INTRODUCTION
2CHAPTER I.  OVERVIEW OF LITERATURE
Intercellular communication is often mediated by interactions of
peptide hormones secreted by cells with receptors at the plasma membrane
of target cells.  A fine–tuned communication between receptors and their
effectors is prerequisite for the coordinated function of all organisms.
Association of several human diseases to hormone receptor pathology
highlights the importance of understanding the mechanisms behind
hormone–receptor interactions and the concurrent triggering of signal
transduction events (Edwards et al. 2000; Dowell 2001; Lu et al. 2002; Wise
et al. 2002).
G protein–coupled receptors (GPCRs) represent a widely distributed
family of membrane proteins, ranging in size from 400 to 1000 amino acid
residues (Lefkowitz 2000).  They have a heptahelical transmembrane (TM)
topology with three extracellular and three (or four) intracellular loops
connecting the seven TM bundle.  The odd number of membrane passing
domains in GPCRs renders their two termini to the opposite side of the cell
such that their N–terminus is on the extracellular side and the C–terminus is
on the intracellular side of the cell, with the receptor being located in the
plasma membrane.  Modifications on both of these termini can lead to
modulation of the receptor activity and function (Schoneberg et al. 1999;
Gether 2000).
GPCRs are believed to exist in several interchangeable conformations
including resting and active states (Lefkowitz 2000).  The most widely
accepted model to account for hormone action involves stabilization of the
3active (activated) conformation of the receptor as an outcome of ligand
binding (Kenakin 1997; Gether and Kobilka 1998).  GPCRs mediate cellular
responses to a variety of extracellular stimuli, such as light, ions, biogenic
amines, amino acids, peptides, hormones, lipids, nucleosides, nucleotides,
neurotransmitters, growth factors, glycoproteins, proteases, and odorants
(Hebert and Bouvier 1998; Gether 2000; Lefkowitz 2000).  Binding of the
specific ligand to its GPCR on the extracellular region of the cell results in
transition of the receptor into the active conformation.  This transition then
results in changes in the physical state of the associated heterotrimeric G
protein (Gabg) such that the GTP–bound form of the a–subunit dissociates
from both the receptor and the stable bg dimer.  Both the GTP–bound
a–subunit and the released bg dimer can modulate diverse cascades of
intracellular signal transduction pathways such as stimulation or inhibition of
adenylate cyclases, activation of phospholipases, and regulation of activity of
protein kinases and K+ and Ca2+ ion channels, thereby culminating in
differential gene transcription and characteristic phenotypic changes in
cellular physiology to meet the current needs of the cell (Dohlman et al.
1991; Schwartz 1996; Schoneberg et al. 1999; Gether 2000).  GPCRs are
therefore the key controllers of such diverse physiological processes as
neurotransmission, cellular metabolism, secretion, cellular differentiation,
growth, sensation to light, odors, taste, and pain as well as inflammatory and
immune responses (Hebert and Bouvier 1998; Gether 2000).  Due to their
participation in such diverse pathways, GPCRs play a very important role in
the fate of the cell and are therefore present in all organisms from
4prokaryotes to the single–celled yeast and multicellular higher eukaryotic
organisms such as plants and humans (Dohlman 2002).
Based on hydrophobicity analyses more than 25% of all proteins coded
in genomes is represented by membrane proteins (Popot and Engelman 2000)
and the human genome encodes more than 1,000 receptors (George et al.
2002), which comprises >1% the human genome (Perez 2003).  The diversity
of ligands that can bind GPCRs, striking differences in the sites and modes
of ligand binding and signal generation, as well as the occurrence of multiple
classes of receptors in the GPCR superfamily, render them by far the
largest family of receptors known to date (Ji et al. 1998; Schoneberg et al.
1999; Rana and Insel 2002).  These diversities indicate the availability of
numerous alternative approaches to clinical and industrial applications (Ji et
al. 1998).
While GPCRs do not share any overall sequence homology, significant
sequence homology is found within several subfamilies.  Based on certain key
sequences, GPCRs are categorized into six major families from A to F
(Gether 2000; Fredriksson et al. 2003).  Family A receptors include the
light–receptor of the visual system rhodopsin and the b2–adrenergic
receptors.  Family B contains receptors that are related to the glucagon
receptor and family C comprises receptors related to the metabotropic
neurotransmitter receptors.  The two minor yet unrelated families D and E
are formed by the fungal yeast Saccharomyces cerevisiae pheromone
receptors Ste2p and Ste3p.  Finally, yet another minor but unique subfamily
of proteins comes from Dictyostelium discoideum to form the four cAMP
receptors of family F.  Among these, the rhodopsin/b2–adrenergic receptors
5of family A form by far the largest superfamily of receptors with over 700
members that contain receptors for odorants, small molecules such as
cathecolamines and amines, some peptides, and glycoprotein hormones
(Gether 2000; George et al. 2002; Fredriksson et al. 2003).
Numerous loss–of–function, heterozygous, inactivating and
constitutively activating mutations, as well as polymorphisms, lack of
expression, mislocalization, failure in attaining the correct oligomeric states,
truncations, and splice variants have been observed in GPCRs that relate to a
wide spectrum of hereditary and somatic disorders and several disease
states from cancer to infertility (Ji et al. 1998; Schoneberg et al. 1999;
Edwards et al. 2000; George et al. 2002).  It is not unanticipated that GPCRs
represent major targets for development of new drug candidates with
potential application in all clinical fields (Hebert and Bouvier 1998).
Understanding the broad range of physiological functions and the modes of
regulation associated with GPCRs can therefore provide a solid foundation
for novel therapeutic interventions in a variety of diseases (Edwards et al.
2000; George et al. 2002).  It is not surprising that over 50% of all modern
drugs and almost one–quarter of the top 100–200 best–selling drugs
modulate GPCR activities (George et al. 2002; Kroeze et al. 2003).
Given the overall common structural features among GPCRs, a detailed
structural analysis using x–ray crystallography should bring insights into
determinants of ligand binding and mechanisms of receptor activation.
However, due to low natural abundance, difficulty in producing and purifying
significant quantities of recombinant protein, and inherent difficulties in
solubilizing and obtaining well–diffracting crystals of the large,
6membrane–bound, lipid–associated GPCRs, such studies have been severely
impeded (Gether and Kobilka 1998).  A noted exception is rhodopsin for
which a high–resolution crystallographic structure has been determined
(Palczewski et al. 2000).  A crystal structure of the extracellular
ligand–binding domain of the metabotropic glutamate receptor with and
without the ligand has also been reported (Kunishima et al. 2000).
The paucity of crystallographic structural information on other GPCRs
have hampered determinations of ligand–receptor interactions and the
events leading to the concurrent activation of the signal transduction
pathway.  An alternative to detailed crystallographic information on GPCRs
has therefore been the analysis of mutant receptors for structure–function
studies.  One area of intense study has been to determine the ligand binding
site as a means to understanding different states of receptors and how the
occupation by ligand may initiate signal transduction.  Results from such
studies are then correlated to the structure of rhodopsin.  However, caution
should be used in such comparisons because rhodopsin has its ligand retinal
covalently attached while all other known GPCRs have external ligands.
Therefore, other GPCRs, including those that belong to the same subfamily
as rhodopsin can differ structurally from rhodopsin.
Studying GPCRs in higher organisms presents great challenges due to
multiple classes of GPCRs and multiple subtypes of the same GPCR present in
the same cell or the same tissue.  This becomes even more complicated when
the same GPCR can bind a variety of different ligands to modulate several
different physiological pathways.  One of the organisms to rise to the
challenge of serving as a good model system to study receptor–ligand
7interactions has been the single–celled yeast Saccharomyces cerevisiae
((Dohlman et al. 1991) and see below).
Based on the completion of sequencing of its whole genome, S .
cerevisiae contains only three GPCRs, two of them being the pheromone
receptors Ste2p and Ste3p, and the third being Gpr1p, which is a
carbohydrate nutrient sensor (Lorenz et al. 2000).  Yeast can exist either as
a diploid or as a single haploid cell of the type a or a, and both the haploid
and the diploid forms of yeast can be maintained easily given the right
conditions.  Haploid a cells secrete the a–factor pheromone, while haploid a
cells secrete the a–factor pheromone.  The two pheromones, a–factor and
a–factor, then bind to their cognate GPCRs, Ste2p and Ste3p, respectively,
located on the opposite cell type.  This reciprocal interaction of the two
pheromones with their corresponding receptors results in the initiation of a
protein kinase–mediated cascade of mating pheromone signal transduction
leading to a change in cell morphology, growth arrest, and activation of a
number of pheromone–responsive genes in preparation for cellular mating
and sexual conjugation of the a and a cells (Blumer et al. 1988; Konopka and
Fields 1992; Kurjan 1992; Sprague 1992; Banuett 1998; Dohlman 2002).
Since in any haploid cell there is only one of the pheromone receptors
present, and the Gpr1p receptor couples to a different Ga protein (Gpa2p
versus the Gpa1p in the pheromone receptors; (Lorenz et al. 2000)), there is
no cross–talk between these GPCRs.  Thus, the interactions between the
pheromone receptor and its pheromone ligand can be studied with great ease
and specificity in yeast.  Moreover, the complex but well–understood mating
signal transduction pathway of yeast involves a MAPK pathway (Ramezani-
8Rad 2003), which shares several common features that are conserved in
higher eukaryotic organisms such as humans.  Yeast is also a very easy
organism to work with due to ease of growing and handling both the stable
haploid and the stable diploid forms, and the ability to use complex, powerful
genetic manipulations.  All these properties of yeast consequently render it a
good model organism for studying and understanding receptor–ligand
interactions (Dohlman et al. 1991; Dohlman 2002).
In our studies, we have chosen to work in the mating type MATa cells
where the pheromone receptor located on the cell surface is Ste2p and its
corresponding pheromone ligand is the tridecapeptide a–factor.  Our studies
favored this system over Ste3p/a–factor because the dodecapeptide
a–factor mating pheromone is very hydrophobic and hard to handle due to
carboxymethylation and farnesylation of its Cys residue located at position
12 on the C–terminus of the peptide.  On the other hand, a–factor is not as
hydrophobic and thus is easily synthesized and manipulated to meet the
needs of our investigations.
Studies that are presented in this dissertation focus on residues
located at specific positions on the extracellular and transmembrane regions
of the Ste2p receptor.  Our approach has been to mutagenize the receptor
and then study the effects these mutations had on the function of the
receptor.  Part II details all the methodologies used throughout the
dissertation.  Part III describes scanning mutagenesis and characterization
of the first and third extracellular loop (EL1 and EL3) residues of Ste2p.
Part IV depicts studies on the mutant receptors with signal–deficient
phenotypes that were identified in Part III.  In these studies, mutations
9from EL1 and EL3 causing signal–deficient phenotypes are introduced into a
receptor with a previously incorporated constitutively activating mutation,
and the biological properties of the resultant mutants are investigated.  Part
V describes studies aimed at determining specific interactions between
residues located on the transmembrane region of Ste2p that were predicted
to interact with one another.  Finally, Part VI gives the overall summary of
the results along with some future directions, and the synopsis of our
current understanding of Ste2p based on the studies presented herewith.
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PART II.  EXPERIMENTAL PROCEDURES
11
CHAPTER I.  MATERIALS AND METHODS
Yeast Strains, Plasmids and Growth Conditions–  For convenience all
the yeast strains that have been used in studies described in this
dissertation are summarized in Table 1 with their relevant genotype
information.  LM102 and LM23–3az yeast strains described by Sen and
Marsh (Sen and Marsh 1994), BJS21 yeast strain described by (Lee et al.
2002), and AAS02 (generated from the LM102 strain by disruption of FAR1;
see below) were used in these studies.  The genotype for LM102 strain is
MATa, bar1, his4, leu2, trp1, met1, ura3, FUS1–lacZ::URA3, ste2–dl (deleted
for the region coding for the a–factor receptor).  LM23–3az has the same
genotype as LM102 except it contains an intact chromosomal STE2 gene
coding for the a–factor receptor.  LM102, LM23–3az and AAS02 strains
carried the bar1 mutant allele, which inactivated the BAR1 protease
responsible for degradation of a–factor, and a FUS1–lacZ gene, which served
as a pheromone–inducible reporter.  AAS02 strain was also far1–D (deleted
for FAR1 protein that is responsible for growth arrest response in yeast).
Growth medium for LM102, LM23–3az and AAS02 contained yeast nitrogen
base medium with ammonium sulfate without amino acids (Difco, Kansas City,
MO) with 2% glucose (SD medium), supplemented with histidine (20 mg/ml),
leucine (30 mg/ml) and methionine (20 mg/ml).  The relevant genotype for
BJS21 strain is MATa, prc1–407, prb1–1122, pep4–3, leu2, trp1, ura3–52,
ste2::kanr (protease–deficient strain disrupted in the region coding for the
a–factor receptor).  This strain carried the prc1, prb1, and pep4 mutant
alleles, which inactivated the proteases carboxypeptidase Y proteinase C,
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Table 1.  Yeast Strains Used in Studies Described in This Dissertation
Strain Relevant Genotype Source
LM102
MATa, bar1, his4, leu2, trp1, met1, ura3,
FUS1–lacZ::URA3, ste2–dl
(Sen and Marsh
1994)
LM23–3az
MATa, bar1, his4, leu2, trp1, met1, ura3,
FUS1–lacZ::URA3
(Sen and Marsh
1994)
AAS02
MATa, bar1, his4, leu2, trp1, met1, ura3,
FUS1–lacZ::URA3, far1::kanr, ste2–dl This Dissertation
BJS21
MATa, prc1–407, prb1–1122, pep4–3,
leu2, trp1, ura3–52, ste2::kanr (Lee et al. 2002)
endopeptidase vacuolar protease B, and endopeptidase vacuolar proteinase A,
respectively.  BJS21 was grown in MLT (Medium Lacking Tryptophan), which
contained yeast nitrogen base medium with ammonium sulfate without amino
acids with 2% glucose (SD medium), 1% casamino acids (Difco), adenine
sulfate (58 mg/ml), arginine (26 mg/ml), asparagine (58 mg/ml), aspartic acid
(140 mg/ml), glutamic acid (140 mg/ml), histidine (28 mg/ml), isoleucine (58
mg/ml), leucine (83 mg/ml), lysine (42 mg/ml), methionine (28 mg/ml),
phenylalanine (690 mg/ml), serine (520 mg/ml), threonine (280 mg/ml),
tyrosine (42 mg/ml), valine (210 mg/ml), and uracil (28 mg/ml).  LM23–3az was
used only to study dominant negative effects of certain mutant receptors on
the function of wild–type (WT) STE2 (see Results section in Part III).
LM102 strain was used as the recipient for the transformation with WT and
site–directed mutant STE2.  Measurement of the pheromone–induced
growth arrest (halo assay), pheromone–induced gene expression (FUS1–lacZ
assay) and determination of pheromone binding were done in the LM102 host
strain.  For studies in Part IV, AAS02 strain was used instead of LM102.
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Most expression studies were carried out in the protease–deficient BJS21
strain if no expression was detectable in the LM102 and AAS02 strains.
The WT STE2 gene with a native promoter was cloned into a yeast/bacterial
shuttle vector pGA314.WT (Abel et al. 1998a) and was used as a template
plasmid for the subcloning of FLAG™ epitope and His6 tag and further
site–directed mutagenesis of the a–factor receptor gene.  This plasmid
carries the TRP1 gene as a selectable marker and is a low copy CEN–based
plasmid.
FAR1 Knock–Out in the LM102 Yeast Strain–  In Part IV, where the
constitutively activating P258L mutation was incorporated into Ste2p and
Ste2p mutants, the LM102 strain was modified prior to being used as the
host strain.  The modification was in the form of disrupting the chromosomal
copy of FAR1 gene by replacement with the kanamycin resistance (kanr)
cassette lest a constitutively active mutant with a strong enough phenotype
to initiate growth arrest response would be unable to cause cell death as a
result of this response.  The kanr cassette was previously modified to yield
the KanMX expression module by fusing the heterologous kanr gene from the
Escherichia coli transposon Tn903 to the transcriptional and translational
control sequences of TEF2 from the heterologous filamentous fungus
Ashbya gossipii (Wach et al. 1994).  This KanMX hybrid module integrated
with high efficiency via homologous recombination at the correct genomic
locus (routinely 70%), and permitted high efficiency selection of
transformants from yeast that are resistant to the aminoglycoside
antibiotic Geneticin® (G418).  FAR1 gene disruption was done as described
previously (Gueldener et al. 2002).  PCR primers were designed to amplify
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from the plasmid pUG6 (Guldener et al. 1996) the region corresponding to
the loxP–KanMX–loxP gene disruption cassette, where expression of the Cre
recombinase allowed excision of the KanMX module by an efficient
recombination between the loxP sites, leaving behind a single loxP site at the
chromosomal locus.  For simplicity purposes, the loxP–KanMX–loxP cassette
will be referred to as kanr throughout the text.  The gene disruption PCR
primers (far1/kanr Forward and far1/kanr Reverse in Table 2) contained
homologous sequences to the ends of the FAR1 ORF and priming sequences
to the kanr gene disruption cassette to result in the replacement of the
entire FAR1 gene locus.  PCR amplification using these primers yielded a
fragment with the expected size of 1.7–kb.  LM102 cells were transformed
with this PCR product and yeast transformants were selected on YEPD
plates containing 200 mg/mL G418 sulfate (Gibco BRL, Germany).  After each
Table 2.  Oligonucleotide Primers Used in Disruption of the FAR1 Gene ORF
Primer Sequence (5'Æ3')
far1/kanr
Forwarda
ATCCACTGGAAAGCTTCGTGGGCGTAAGAAGGCAATCTATTAATGCAGCTGAAGCTTCGTACGC
far1/kanr
Reversea
AAAAGCAAAAGCCTCGAAATACGGGCCTCGATTCCCGAACTACTAGCATAGGCCACTAGTGGATCTG
Check
Forwardb
GACCCGGTCGTTTCAGAATGC
Check
Reverseb
GAAGAGGGTTACCCGGCTGC
Probe
Forwardc
AAGACACCAACAAGAGTTTCG
Probe
Reversec
GAGGTTGGGAACTTCCAGGGTCTG
a Sequences homologous to FAR1 are underlined and those sequences that are not underlined are the priming
sequences to amplify kanr.  For simplicity kanr is used to represent the loxP–KanMX–loxP gene disruption cassette
describedpreviously (Guldener et al. 1996).  The Start and Stop codons in the FAR1 ORF are double interlined.
b These primers were designed about 500 bases upstream and downstream of the FAR1 ORF.
c These primers were designed to start inside the FAR1 ORF right after the Start codon (ATG) and right before
the Stop codon (CTA; reverse complement of the UAG Stop codon) so that their sequences would not overlap with
the far1/kanr Forward and Reverse PCR primers, which contained the Start and Stop codons of the FAR1 ORF.
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of the successful transformants were re–streaked onto YEPD plus G418
plates, only transformants growing well were chosen for further analysis.
Three candidate colonies referred to as AAS01, AAS02, and AAS03 were
obtained from the first plates that remained resistant to G418 on the
second plates after selection by re–streaking.  Detection of the correct
gene disruption of the FAR1 ORF was done by either diagnostic PCR or
Southern blot analysis.  For diagnostic PCR, genomic DNA prepared from
AAS01, AAS02, and AAS03 were subjected to PCR amplification using the
forward and reverse Check primers (Table 2) located ~500–nt upstream of
the Start codon (ATG) and ~500–nt downstream of the Stop codon (CTA;
reverse complement of the UAG Stop codon) of the disrupted FAR1 gene.
Genomic integration of the disruption cassette was verified for AAS02 and
AAS03 using the forward and reverse Probe primers (Table 2) that were
located into the kanr gene immediately following the Start codon (ATG) or
covering sequences up to the Stop codon (CTA) for the forward and reverse
Probe primers, respectively.  These Probe primers were also used to amplify
the FAR1 ORF from LM102 strain, which harbored an intact FAR1 locus.  The
resultant DNA fragment was then used to prepare a FAR1 probe using
random 6–mer (IDT, Coralville, IA) or 9–mer (Megaprime Labeling Kit,
Amersham, Piscataway, NJ) oligos and 32P–ATP (MP Biomedicals, Irvine, CA),
for use in the Southern blotting analysis of AAS01, AAS02, and AAS03.  As
previously confirmed by the diagnostic PCR analysis, AAS02 and AAS03 both
appeared to have integrated the kanr cassette into their genome at or near
the FAR1 locus.  All three candidate strains were also tested for biological
activity in an a–factor growth arrest assay after being transformed with a
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plasmid harboring the WT Ste2p receptor.  As expected from the PCR and
Southern blotting analyses, AAS01 gave halo sizes similar to LM102
transformed with the same plasmid in the presence of 1m g a–factor,
indicating failure in the FAR1 gene disruption.  When tested under similar
conditions, AAS02 resulted in no formation of halos, while AAS03 gave
partial halos.  This indicated that the FAR1 gene locus in AAS02 was fully
integrated with the kanr gene disruption cassette, but the same locus was
not disrupted fully in AAS03 that a partial function in Far1p was observed.
Based on these investigations, AAS02, which was confirmed to be the only
null mutant of FAR1 (i.e. far1::kanr) was used as the recipient of the mutant
Ste2p receptors generated in Part IV.
Subcloning of FLAG™ Epitope and His6 Tag–  The first step in
generation of site–directed mutant STE2 was the creation of a pGA314.WT
plasmid coding a STE2 gene product tagged with FLAG™ epitope and His6
affinity sequence at the 3' end of the STE2 gene.  For this, the plasmid
pNED described by David et al. (David et al. 1997) was used as the source of
the C–terminal epitope tags.  STE2 in pNED contains an 81–bp region at its
3' end that codes for 24–bp FLAG™ epitope (DYKDDDDK), 30–bp Gly–rich
flexible tether (TGVPRGSGSS), 18–bp His6 affinity tag (HHHHHH), and
9–bp unrelated sequences (SSG) followed by a stop codon.  The desired
region of STE2 containing the 3' tagged sequences was removed by digestion
with SalI and the thus generated 121–bp fragment was gel purified using
MERmaid kit (Bio 101, Carlsbad, CA).  The pGA314.WT plasmid was digested
with SalI which produced a 6.272–kb fragment coding for the STE2 gene
that lacked its 3' end sequences.  This fragment was dephosphorylated with
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shrimp alkaline phosphatase (USB, Cleveland, OH) and gel purified using
Geneclean III kit (Bio101).  The 121–bp fragment insert purified from the
pNED vector was ligated into the 6.272–kb fragment purified from
pGA314.WT vector using T4 DNA ligase (Promega, Madison, WI).  Correct
orientation of the insert was confirmed by DNA sequencing.  The 6.393–kb
plasmid thus generated coded for the STE2 gene with 3' FLAG™ epitope
(FT) and His6 tag (HT) sequences, and allowed expression of STE2 under its
native promoter.  This plasmid was referred to as pGA314.STE2.FT.HT and
it served as the template for further site–directed mutagenesis in all
studies except those in Part IV, where the plasmid pGA314.STE2 was used
as the template for further mutagenesis.
Primers and Sequencing–  All primers were purchased from
Sigma/Genosys (The Woodlands, TX).  Sequences of the primers used are
presented in Table 3 (for Cys–scanning mutagenesis of EL1 described in Part
III), Table 4 (for Ala–scanning mutagenesis of EL1 described in Part III);
Table 5 (for Cys–scanning mutagenesis of EL3 described in Part III), and
Table 6 (for site–directed mutagenesis studies of Ste2p described in Parts
IV and V).  DNA sequencing was carried out in the DNA sequencing facility
located on the campus of the University of Tennessee.
Construction of Cys–less Ste2p.FT.HT and Cys–less Ste2p–
Single–stranded phagemid DNA of pGA314.STE2.FT.HT or pGA314.STE2
was prepared by infecting CJ236 Escherichia coli strain (dut– ung–) carrying
pGA314.STE2.FT.HT or pGA314.STE2 with the helper phage M13K07 (Vieira
and Messing 1987).  Oligonucleotide–directed mutagenesis of
single–stranded phagemid DNA of pGA314.STE2.FT.HT or pGA314.STE2 was
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Table 3.  Primers Used in Part III for Cys–Scanning Mutagenesis of Ste2p EL1
Oligo Name Sequence (5'Æ3')b
C59Sa TGGTGTCAGATCTGGTGCAGCTGC
C252Sa CTCATAATGTCATCTCAATCTTTGTTGGTTCC
K100C GCATTCTGCACTCTATTTTTGCTATTTACTGTCTAATTACTC
Y101C GCACTCTATTTTAAATGTTTACTGTCTAATTACTC
L102C GCACTCTATTTTAAATATTGCCTGTCTAATTACTCTTCAG
L103C GCACTCTATTTTAAATATTTATGCTCTAATTACTCTTCAG
S104C CTCTATTTTAAATATTTACTGTGTAATTACTCTTCAGTG
N105C CTCTATTTTAAATATTTACTGTCTTGTTACTCTTCAGTGAC
Y106C CTGTCTAATTGCTCTTCAGTGACTTACGC
S107C CTGTCTAATTACTGTTCAGTGACTTACGC
S108C CTGTCTAATTACTCTTGCGTGACTTACGCTCTC
V109C CTGTCTAATTACTCTTCATGCACTTACGCTCTCACC
T110C CTGTCTAATTACTCTTCAGTGTGTTACGCTCTCACCGG
Y111C CTCTTCAGTGACTTGCGCTCTCACCGG
A112C CTCTTCAGTGACTTACTGTCTCACCGGATTTCC
L113C CAGTGACTTACGCTTGCACCGGATTTCCTCAG
T114C CAGTGACTTACGCTCTCTGCGGATTTCCTCAG
G115C GTGACTTACGCTCTCACCTGCTTTCCTCAGTTCATCAG
F116C CGCTCTCACCGGATGTCCTCAGTTCATCAG
P117C CGCTCTCACCGGATTTTGTCAGTTCATCAGTAGAGG
Q118C CGCTCTCACCGGATTTCCTTGCTTCATCAGTAGAGGTG
F119C CACCGGATTTCCTCAGTGCATCAGTAGAGGTG
I120C CCGGATTTCCTCAGTTCTGCAGTAGAGGTGACG
S121C CCTCAGTTCATCTGTAGAGGTGACG
R122C CCTCAGTTCATCAGTTGCGGTGACGTTCATG
G123C CAGTTCATCAGTAGATGTGACGTTCATGTTTATGG
D124C CAGTTCATCAGTAGAGGTTGCGTTCATGTTTATGG
V125C CATCAGTAGAGGTGACTGTCATGTTTATGGTGC
H126C CAGTAGAGGTGACGTTTGTGTTTATGGTGCTAC
V127C GAGGTGACGTTCATTGTTATGGTGCTAC
Y128C GGTGACGTTCATGTTTGTGGTGCTACA
G129C GACGTTCATGTTTATTGTGCTACAAATATAATTCAAGTCC
A130C CGTTCATGTTTATGGTTGTACAAATATAATTCAAGTCC
T131C CGTTCATGTTTATGGTGCTTGCAATATAATTCAAGTCC
N132C CGTTCATGTTTATGGTGCTACATGTATAATTCAAGTCC
I133C GGTGCTACAAATTGCATTCAAGTCCTTCTTGTGGC
I134C GGTGCTACAAATATATGTCAAGTCCTTCTTGTGGC
Q135C GGTGCTACAAATATAATTTGCGTCCTTCTTGTGGC
a Used to generate STE2.FT.HT that is devoid of its native cysteine residues.  This construct was
referred to as the Cys–less STE2.FT.HT, which served as the template for scanning and site–directed
mutagenesis of STE2 in Parts III and V.  For Part IV, Cys–less STE2 was used as the template.
b Codons for the mutated amino acid residues are shown in bold face and the mismatched base to
incorporate the intended mutation is underlined.
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Table 4.  Primers Used in Part III for Ala–Scanning Mutagenesis of Ste2p EL1
Oligo Name Sequence (5'Æ3')b
L102A GCACTCTATTTTAAATATGCACTGTCTAATTACTCTTCAGTG
L103A GCACTCTATTTTAAATATTTAGCGTCTAATTACTCTTCAGTG
S104A GCACTCTATTTTAAATATTTACTGGCCAATTACTCTTCAGTGACTTACGC
N105A GCACTCTATTTTAAATATTTACTGTCTGCTTACTCTTCAGTGACTTACGC
Y106A GCACTCTATTTTAAATATTTACTGTCTAATGCCTCTTCAGTGACTTACGC
S107A CTGTCTAATTACGCTTCGGTGACCTACGCTCTCACCGG c
S108A CTGTCTAATTACTCTGCGGTGACCTACGCTCTCACCGG c
V109A CTGTCTAATTACTCTTCAGCGACTTACGCTCTCACCGGTTTTCCTCAG c
T110A CTGTCTAATTACTCTTCAGTGGCTTACGCTCTCACCGGTTTTCCTCAG c
Y111A CTGTCTAATTACTCTTCAGTGACTGCCGCTCTCACCGGTTTTCCTCAG c
A112Ga CTGTCTAATTACTCTTCAGTGACTTACGGTCTCACCGGATTTCCTCAG
L113A CTGTCTAATTACTCTTCAGTGACTTACGCTGCCACCGGTTTTCCTCAG c
T114A CAGTGACTTACGCTCTCTGCGGATTTCCTCAG
a The native residue at position 112 was Ala.  It was replaced with Gly instead.
b Codons for the mutated amino acid residues are shown in bold face and the mismatched base to
incorporate the intended mutation is underlined.
c Mismatched bases that resulting in silent mutations that allowed incorporation of a new restriction
site are underlined without being bold faced.
Table 5.  Primers Used in Part III for Cys–Scanning Mutagenesis of Ste2p EL3
Oligo Name Sequence (5'Æ3')a
L264C GGTTCCATCGATAATATTCATCTGTGCATACAGTTTGAAACC
A265C CGATAATATTCATCCTCTGTTACAGTTTGAAACCAAACC
Y266C CGATAATATTCATCCTCGCATGCAGTTTGAAACCAAACC
S267C CCTCGCATACTGTTTGAAACCAAACC
L268C CCTCGCATACAGTTGTAAACCAAACCAGG
K269C CGCATACAGTTTGTGCCCAAACCAGGG
P270C GCATACAGTTTGAAATGCAACCAGGGAACAGATGTC
N271C GCATACAGTTTGAAACCATGTCAGGGAACAGATGTC
Q272C CAGTTTGAAACCAAACTGTGGAACAGATGTCTTGAC
G273C CAGTTTGAAACCAAACCAGTGTACAGATGTCTTGACTACTGTTGC
T274C CCAAACCAGGGATGTGATGTCTTGACTACTGTTGC
D275C CCAAACCAGGGAACATGTGTCTTGACTACTGTTGC
V276C CCAGGGAACAGATTGCTTGACTACTGTTGC
L277C GGGAACAGATGTCTGTACTACTGTTGCAAC
T278C GGAACAGATGTCTTGTGTACTGTTGCAACATTACTTGC
a Codons for the mutated amino acid residues are shown in bold face and the mismatched base to
incorporate the intended mutation is underlined.
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Table 6. Primers Used in Parts IV–V! for Site–Directed Mutagenesis of Ste2p
Oligo Name Sequence (5'Æ3')a
P258Lb GTCATCTCAATCTTTGTTGGTTCTATCGATAATATTCATCC
R58Ac,d GCCATTATGTTTGGTGTCGCATCTGGTGCAGCTGCTTTGAC
R58Dc,d GCCATTATGTTTGGTGTCGATTCTGGTGCAGCTGCTTTGAC
R58Ec,d GCCATTATGTTTGGTGTCGAATCTGGTGCAGCTGCTTTGAC
R58Qc,d GCCATTATGTTTGGTGTCCAATCTGGTGCAGCTGCTTTGAC
Q135Ec GGTGCTACAAATATAATTGAAGTCCTTCTTGTGGC
Q135Rc GGTGCTACAAATATAATTAGAGTCCTTCTTGTGGC
E143Ac CCTTCTTGTGGCTTCTATTGCGACTTCACTGGTGTTTCAG
E143Kc CCTTCTTGTGGCTTCTATTAAGACTTCACTGGTGTTTCAG
K225Ac GTCATTTGTCCTGGTAGTTGCATTGATTTTAGCTATTAGATC
K225Ec GTCATTTGTCCTGGTAGTTGAATTGATTTTAGCTATTAGATC
D275Ac CCAAACCAGGGAACAGCTGTCTTGACTACTGTTGC
D275Rc CCAAACCAGGGAACACGTGTCTTGACTACTGTTGC
D275Qc CCAAACCAGGGAACACAAGTCTTGACTACTGTTGC
a Codons for the mutated amino acid residues are shown in bold face and the mismatched base to
incorporate the intended mutation is underlined.
b This primer, which was used in studies described under Part IV of this dissertation, was designed to
also incorporate the C252S mutation (underlined, not bold faced) to maintain the Cys–less form of the
receptor.  To see the mismatched bases in C252S please refer to its corresponding entry in Table 3.
c These primers were used in studies described under Part V of this dissertation.
d These primers were designed to also incorporate the C59S mutation (underlined, not bold faced) to
maintain the Cys–less form of the receptor.  To see the mismatched bases in C59S please refer to its
corresponding entry in Table 3.
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constructed as described previously (Kunkel 1985; Kunkel et al. 1987).  The
product of the mutagenesis reaction mixture was transformed into DH5a
(Life Technologies, Inc., Gaithersburg, MD) E. coli strain, and transformants
were selected on ampicillin–containing plates.  Plasmids were then isolated
from transformants using the Wizard Miniprep kit (Promega).  After
sequencing of the isolated plasmids to confirm correct incorporation of the
intended mutations (C59S and C252S), constructs were transformed into
yeast strain LM102 or AAS02 (ste2 deletion strains), and transformants
were selected by their growth on medium lacking tryptophan.
Scanning Mutagenesis of EL1 and EL3, the First and Third
Extracellular Loops of Ste2p, and Site–Directed Mutagenesis of the
Transmembrane Regions of Ste2p–  The plasmid, referred to as
pGA314.Cys–less.STE2.FT.HT, served as the template on which Cys–scanning
mutagenesis of EL1 and EL3, and Ala–scanning mutagenesis of EL1 of Ste2p
were performed.  For studies in Part IV, the plasmid referred to as
pGA314.Cys–less.STE2 served as the template on which Cys substitutions of
EL1 and EL3, combined with the constitutively activating mutation (P258L) to
generate double receptor mutants, were performed.  The product of the
mutagenesis reaction mixture was transformed into DH5a  (Life
Technologies, Inc.) E. coli strain, and transformants were selected on
ampicillin–containing plates.  Plasmids were then isolated from transformants
using the Wizard Miniprep kit (Promega).  Each construct was subjected to
sequencing to confirm correct incorporation of the intended mutations prior
to transformation into the ste2 deletion yeast strain LM102, AAS02 or
BJS21 and subsequent selection of transformants by their growth on the
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medium lacking tryptophan.  In the case of non–functional mutant receptors
(as determined by growth arrest assay; see Results sections in Part III and
Part V), plasmids from three independent isolates were transformed into
yeast to confirm that the observed phenotypes were due to the intended
mutation but not due to the presence of spurious mutations.
Measuring of Protein Expression Levels by Immunoblot–  S.
cerevisiae strains LM102, AAS02 and BJS21 (strains with ste2 deletion),
and LM102(pGA314.STE2 or pGA314.mutantSTE2), AAS02(pGA314.STE2 or
pGA314.mutantSTE2) and BJS21(pGA314.STE2 or pGA314.mutantSTE2)
[strains containing a plasmid encoding Ste2p or mutant Ste2p] were grown,
and membranes containing or lacking Ste2p and mutant Ste2p receptors
were prepared as described previously (David et al. 1997).  All manipulations
with membranes and all purification steps were carried out at 4 ˚C in the
presence of protease inhibitors (1.0 mg/ml leupeptin, 1.0 mg/ml pepstatin A,
and 17.4 mg/ml PMSF).  Membranes were solubilized in sample buffer [50 mM
Na2CO3, 50 mM dithiothreitol (DTT), 15% (w/v) sucrose, 2.5% SDS].  Equal
amounts of solubilized membrane proteins (2–20 mg) were resolved by
SDS–PAGE (10%), electrophoretically transferred to immobulin P membrane
(Millipore, Bedford, MA), and probed with FLAG™ antibody (IBI, Kodak,
Rochester, NY).  The resulting immune complexes were detected by
horseradish peroxidase conjugated goat anti–mouse antibodies, and
visualized by chemiluminescence (ECL kit, Amersham, Piscataway, NJ).  For
studies in Part IV where STE2 lacking an epitope tag was used, the
membranes were probed with STE2 antibody for the N–terminus (kindly
provided by Dr. James B. Konopka, State University of New York, Stony
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Brook, NY) or for the C–terminus (Virusys Corporation, Sykesville, MD) of
Ste2p.  The resulting immune complexes were then detected by horseradish
peroxidase conjugated anti–rabbit (for N–terminal epitope) or anti–chicken
(for C–terminal epitope) antibodies.  Immune complexes were visualized by
enhanced chemiluminescence (ECL kit, Amersham, Piscataway, NJ) or
enhanced chemifluorescence (ECL–Plus kit, Amersham).
Growth Arrest (Halo) Assay–  Yeast nitrogen base medium with
ammonium sulfate without amino acids with 2% glucose (SD medium),
supplemented with histidine (20 mg/ml), leucine (30 mg/ml) and methionine
(20 mg/ml), was overlaid with 4 ml of cell suspension (1.25 X 106 cells/ml,
1.1% Nobel agar).  Filter discs (sterile blanks from Difco), 6 mm in diameter,
were impregnated with 10 m l portions of a–factor solutions at various
concentrations and placed onto the overlay.  The a–factor used was
[Nle12]a–factor, which is isosteric, equiactive, and has the same binding
affinity as the wild–type pheromone (Raths et al. 1988).  The plates were
incubated at 30 ˚C for 24–36 h and then observed for clear zones (halos)
around the discs.  The data were expressed as the diameter of the halo
including the diameter of the disc.  All assays were carried out at least
three times with no more than a 2 mm variation in halo size at a particular
amount of a–factor.  A molar extinction coefficient of 13,500 at 280 nm was
used for adjusting a–factor concentration throughout the study.  The data
were plotted as halo size versus the amount of peptide, and linearized by
regression analysis using Prism™ software (GraphPad, San Diego, CA).  To
compare the relative activities of a–factor with different receptors, the
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amount of peptide producing a halo of a particular size was determined from
the regression line of dose–response curves.
FUS1–lacZ Gene Induction Assay–  S. cerevisiae LM102, LM23–3az,
and AAS02 contain a FUS1–lacZ gene that is inducible by mating pheromone.
Cells were grown overnight in SD medium supplemented with required amino
acids at 30 ˚C to 5 X 106 cells/ml, washed by centrifugation, and grown for
one doubling (hemocytometer count) at 30 ˚C.  Induction was performed by
adding 0.5 ml of a –factor at various concentrations to 4.5 ml of
concentrated cells (1 X 108 cells/ml) to give a final a–factor concentration of
0, 1 X 10–10, 1 X 10–9, 1 X 10–8, 1 X 10–7, 1 X 10–6, and 1 X 10–5 M.  The mixtures
were vortexed and placed at 30 ˚C with shaking for 2 h.  After this
incubation, cells were harvested by centrifugation, and each pellet was
resuspended and assayed for b–galactosidase activity (expressed as Miller
Units) in duplicate or triplicate by modification (Kippert 1995) of a standard
protocol (Miller 1972; Guarente 1983) us ing o–nitrophenyl
b–D–galactopyranoside (ONPG, Sigma, St. Louis, MO) as the substrate.  EC50
(concentration of peptide required for half–maximal activation of the
receptor) and Emax (maximal activation obtained from the highest peptide
concentration, 1 X 10–6 or 1 X 10–5 M) values were calculated with a 95%
confidence interval using Prism™ software (GraphPad) with a sigmoidal
dose–response curve fitting, variable slope equation, which was Y = Bottom +
((Top – Bottom)/(1 + 10(logEC50 – X))), where X is the logarithm of concentration
and Y is the response.  Since regression analysis used logarithmic values for
concentration of a–factor and since logarithm of zero is infinite, a non–zero
value lower than the lowest assay concentration of a–factor was used to
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represent zero concentration of a–factor.  Therefore, in all FUS1–lacZ
assays the lowest concentration  of a –factor (10–11 M or 10–9 M)
corresponded to zero concentration of a–factor.  Each experiment was
carried out at least two times with the results similar in each assay and
results representing average of at least two experiments.
Binding Assays–  Saturation and competition binding assays were
performed using [3H]a–factor.  Cells were grown overnight at 30 ˚C and
harvested at 1.0 X 107 to 1.5 X 107 cells/ml by centrifugation at 5000 X g at
4 ˚C.  The pelleted cells were washed two times in ice–cold YM–1 medium
(Abel et al. 1998b) and resuspended at 6.25 X 107 cells/ml.  [3H]a–factor
was prepared by reduction of [dehydroproline8, Nle12]a–factor as described
previously (Raths et al. 1988).  The competition binding assays were started
by the addition of a fixed concentration of [3H]a–factor typically at the Kd
of the receptor (10 nM) and varying concentrations of cold a–factor as
described in detail elsewhere (Abel et al. 1998b; Liu et al. 2000).  In
saturation binding assays, various concentrations of [3H]a–factor were
added to a cell suspension.  Specific binding was determined by subtracting
counts associated with the LM102, AAS02 or BJS21 ste2 deletion strains
from counts bound to the strains harboring WT or mutant receptors.  Each
experiment was carried out at least three times with similar results.
Nonspecific binding of labeled a–factor to filters in the absence of cells was
less than 20 cpm.  Data curves for competition and saturation binding assays
were fitted from at least eight triplicate data points using Prism™ software
(GraphPad) with nonlinear regression one site competition, and nonlinear
regression one site saturation hyperbola equations, respectively.  The Ki
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values for competition binding assays were calculated by using the equation
of Cheng and Prusoff (Cheng and Prusoff 1973), where Ki = EC50/(1 +
[ligand]/Kd).  The saturation binding equation for the total binding, which
includes specific binding together with non–specific binding, is Y = ((Bmax/(X
+ Kd)) + NSX).  Here Bmax denotes the maximal density of receptor sites, X
denotes the concentration of radioligand, Kd denotes the radioligand
equilibrium dissociation constant, Y denotes total binding, and NS denotes
the slope for non–specific binding in a straight line that intercepts the axes
at a value of zero.
Prospect–  PROSPECT is a computer package for finding an optimal
alignment between a protein sequence and a protein structural fold (Xu and
Xu 2000).  PROSPECT finds the globally optimal sequence–structure
alignment and does so in an efficient manner, when considering both
alignment gap penalty and pairwise potential between residues that are
spatially close.  A neural network assessment for the reliability of the fold
recognition is given by PROSPECT (Xu 2002).  The atomic structures were
generated using MODELLER (Sali and Blundell 1993) based on the alignments
obtained from threading.  PROSPECT has been applied successfully to many
proteins with unknown experimental structures.
3–D Modeling–  The first extracellular loop of Ste2p including a few
residues on TM2 and TM3 was modeled in the range of residues 100–137
through the consensus of several tools for transmembrane domain
prediction, including SOSUI (Hirokawa et al. 1998) and MEMSAT (Jones et
al. 1994).  Secondary structure predictions for EL1 were carried out using
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two best–known secondary structure prediction tools, i.e., PSIPRED (Jones
1999) and PHD (Rost and Sander 1993), both of which gave similar results.
Synthesis of the LSNYSSVTYALTGFPQFISRGDVHVYGATNG
Peptide–  A peptide corresponding to residues 103–132 of the first
extracellular loop of Ste2p was prepared using a solid phase strategy.  For
convenience a glycine residue was added to the carboxyl terminus of the
peptide.  In this paper we refer to this synthetic peptide as EL1(103–132).
All reagents and solvents used for the solid phase peptide synthesis of the
thirty–one amino acid residue fragment were analytical grade and were
purchased from Advanced Chem. Tech. (Louisvil le, KY),
Calbiochem.–Novabiochem. Corp. (San Diego, California), VWR Scientific
(Piscataway, NJ) and Aldrich Chemical Co. (Milwaukee, WI).  High
performance liquid chromatography (HPLC) grade dichloromethane (CH2Cl2),
acetonitrile (CH3CN), methanol (MeOH) and water were purchased from
VWR Scientific and Fisher Scientific (Springfield, NJ).  Automated
synthesis of EL1(103–132) was carried out on an Applied Biosystem 433A
peptide synthesizer (Applied Biosystem, Foster City, CA) using preloaded
Fmoc–Gly–Wang resin (0.65 mmol/gm, Advanced Chem. Tech.) on 0.1 mmol
scale.  The 0.1 mmol FastMoc chemistry of Applied Biosystem was used for
the elongation of the peptide chain with an HBTU/HOBt/DIEA catalyzed
coupling step using 10 equivalents of protected amino acids.  For the
fragment corresponding to the first 10 amino acid residues, single coupling,
and after that double coupling, of amino acids was used to avoid formation of
deletion peptides.  Acetic anhydride capping was used after each coupling to
improve the purity of the peptide.  Purity of the peptide fragments was
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checked after 10 and 20 amino acid residues had been assembled, by
cleaving a small amount of the protected peptide fragment from the resin.
After complete chain assembly, the N–a–deprotected peptidyl resin
was washed thoroughly with 1–methyl–2–pyrrolidinone and CH2Cl2 and dried
in vacuo for 4–5 h.  The peptide was cleaved from the resin support with
simultaneous side chain deprotection using TFA (10 ml), crystalline phenol
(0.75 g), thioanisol (0.5 ml), water (0.5 ml), and 1,2–ethane dithiol (0.25 ml)
(King et al. 1990).  Filtrates from the cleavage mixture were collected,
combined with TFA washes of the resin, concentrated under reduced
pressure, and treated with cold ether to precipitate the crude product.
The crude peptide so obtained was purified by reversed phase HPLC
(Hewlett–Packard Series 1050) on a semi–preparative Vydac (Hesperia, CA)
reverse phase polymer column with detection at 220 nm.  Because of the
strong aggregating tendency of the peptide in water, the crude product (5
mg) was dissolved in 1 ml 50% TFA/Water, applied to the column, and eluted
with a linear gradient of CH3CN/Water containing 0.1% TFA and 10% to 60%
CH3CN over 90 min with a flow rate of 1.5 ml/min.  Fractions were analyzed
by reversed phase HPLC (Hewlett–Packard Series 1050) on an analytical
Vydac reversed phase polymer column with detection at 220 nm.  Fractions
of over 99% homogeneity were pooled and subjected to lyophilization.  The
purity of the final peptide was assessed by electron spray ionization mass
spectrometry (ESI–MS, Peptido Genic Inc., Livermore, CA) and by amino acid
analysis (Biopolymer lab, Brigham and Women’s Hospital, Cambridge, MA).
Molecular weight of the peptide was calculated to be 3320.61 (monoisotopic)
and observed by mass spectrometry (MS) to be 3321.58.
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Circular Dichroism (CD) Analysis–  CD studies of EL1(103–132) were
done from 260–190 nm under nitrogen purge using a cylindrical cuvette with
0.01 cm path length.  Spectra were recorded on an Aviv 62DS
spectrophotometer (AVIV Associates, Lakewood, NJ) interfaced to a
computer for use in all mathematical calculations.  The instrument was
calibrated with D(+)–10–camphorsulphonic acid and all measurements were
carried out using a bandwidth of 1 nm and an averaging time of 0.5 sec.  The
final spectrum was the average of 5 scans.  The background reference
spectrum was collected under identical conditions.  Prior to calculation of
final ellipticities, all spectra were corrected by subtracting the reference
spectrum and the plots were created using the Sigma Plot 5.0 software
(Jandel Scientific, San Rafael, CA).  In general, measurements were made at
peptide concentrations of 1 X 10–4 to 3 X 10–4 M.  The concentration of the
solution was determined spectrophotometrically using tyrosine as standard
or by amino acid analysis.  The extinction coefficient for Tyr at 280 nm was
taken as 1340 M–1–cm–1 (Carpenter et al. 1999).  CD intensities were
expressed as mean residue ellipticities (deg–cm2/decimol).
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PART III.  SCANNING MUTAGENESIS OF THE FIRST AND
THIRD EXTRACELLULAR LOOPS, EL1 AND EL3, OF Ste2p
FOR STRUCTURE–FUNCTION STUDIES
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Part III has been published in part as "Ayça Akal–Strader, Sanjay
Khare, Dong Xu, Fred Naider, and Jeffrey M. Becker (2002).  Residues in
the First Extracellular Loop of a G Protein–Coupled Receptor Play a Role in
Signal Transduction.  J. Biol. Chem. 277: p.30581–30590."  Dr. Sanjay Khare
in Dr. Naider's laboratory was responsible for the synthesis and purification
of a –factor, and circular dichroism studies of the synthetic peptide
corresponding to the sequence of the first extracellular loop (EL1) of Ste2p.
Dr. Dong Xu was responsible for modeling of the peptide corresponding to
the sequence of EL1 of Ste2p.  Ayça Akal–Strader in Dr. Becker's
laboratory was responsible for the design of experiments, construction of
plasmids, mutagenesis of Ste2p and characterization of the mutant
receptors by activity and binding studies.
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CHAPTER I.  INTRODUCTION
Detailed analysis of GPCRs has suggested that for larger ligands, such
as glycoproteins and peptide hormones, extracellular domains contribute
binding determinants (Baldwin 1994; Coughlin 1994; Ji et al. 1998; Marshall
2001) whereas for smaller ligands, such as catecholamines, the ligand binding
pocket is formed by transmembrane domains (Trumpp-Kallmeyer et al. 1992;
Baldwin 1994).  More than one extracellular region was found to participate
in ligand binding to secretin, human P2Y1, protease–activated thrombin
receptor 1, human prostaglandin E–prostanoid 2 (EP2), and cholecystokinin–A
receptors (Holtmann et al. 1996; Hoffmann et al. 1999; Moro et al. 1999;
Stillman et al. 1999; Blackhart et al. 2000; Giragossian and Mierke 2001).  An
extracellular loop was proposed to provide determinants for ligand binding
and/or ligand selectivity to prostaglandin EP3, lutropin luteinizing
hormone/choriogonadotropin, human follicle–stimulating hormone, human EP2
and EP4, monocyte chemoattractant protein–1 receptor 2, opioid
receptor–like 1, and aminergic receptors (Audoly and Breyer 1997; Ryu et al.
1998a; Ryu et al. 1998b; Stillman et al. 1998; Han et al. 1999; Mouledous et
al. 2000; Shi and Javitch 2002).  Involvement of extracellular loops in ligand
binding has been demonstrated directly by labeling of loops with
photo–affinity peptide probes (Behar et al. 1999; Boucard et al. 2000;
Greenberg et al. 2000).  The N–terminus of secretin receptor and
corticotropin–releasing factor receptor 1 were found to play an important
role in interaction with ligand (Dong et al. 1999; Wille et al. 1999; Nielsen et
al. 2000).  In addition, extracellular loops have been the focus for structural
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studies and modeling in several GPCRs (Piserchio et al. 2000; Giragossian and
Mierke 2001; Ruan et al. 2001; Schreier 2001; Zhang 2002).  Finally, GPCRs
have been identified in which large chimeric replacements of extracellular
regions have caused dissociation of high affinity binding from receptor
activation (Holtmann et al. 1996).  A number of experiments have attempted
to identify Ste2p residues or regions involved in ligand binding.  Chimeric
receptors between the closely related S. cerevisiae and S. kluyveri a–factor
receptors implicated the involvement of portions of EL1 (extracellular loop
one), EL3, and the N–terminal extracellular region of TM1 (transmembrane
one) in the specificity of ligand recognition (Sen and Marsh 1994; Sen et al.
1997).  Studies with random mutagenesis of Ste2p and screening for
receptors responding to antagonists proposed an important role for F55 in
TM1 in both ligand binding and signal transduction (Abel et al. 1998a).  Using
site–directed mutagenesis of Ste2p and different a–factor analogues, Lee
and coworkers (Lee et al. 2001) suggested that the tenth residue of
a–factor was in close proximity to S47 and T48 in TM1 of Ste2p.
Measurement of biophysical properties of fluorescent a–factors bound to
Ste2p indicated that the binding pocket was formed by both hydrophobic
and hydrophilic regions suggesting contributions to ligand binding from both
extracellular and transmembrane regions of the receptor (Ding et al. 2001).
Mutational analysis of the putative glycosylation sites in the N–terminus and
on EL1 indicated that glycosylation was not required for pheromone binding
and receptor activation (Mentesana and Konopka 2001).  Finally, a recent
photo–affinity labeling study identified a region of Ste2p spanning portions
of TM6, EL3 and TM7 as the site of cross–linking to the side chain of
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position 1 of a–factor (Henry 2002).  Despite all of these studies, no
previous analysis has discriminated specific residues in the extracellular
loops involved in binding and/or receptor activation.
Here we report our studies on the residues of EL1, the first
extracellular loop, and EL3, the third extracellular loop, of Ste2p.  Our
methodology included Cys–scanning mutagenesis of EL1 over the residues
K100–Q135; Ala–scanning mutagenesis of EL1 over the residues L102–T114;
and Cys–scanning mutagenesis of EL3 over the residues L264–T278.
Following mutagenesis of these loops, we characterized most of the thus
generated mutants by a variety of biological and biochemical techniques,
such as activity assays using growth arrest (halo) assay and FUS1–lacZ
reporter gene induction assay, saturation and competition binding assays,
and western blotting analysis.
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CHAPTER II.  RESULTS
Construction of a Functional, Tagged Ste2p Devoid of Cysteine
Residues–  C–terminally tagged Ste2p (FLAG™ epitope and His6 tag) has
been constructed with wild–type behavior for both pheromone binding and
activation of the signal transduction pathway (David et al. 1997; Martin et al.
1999; Dube et al. 2000).  These tags were engineered to allow detection of
receptors on western blots and to serve for their selective purification using
affinity chromatography.  To create a template for Cys–scaning and
Ala–scaning mutagenesis, we removed the two native Ste2p Cys residues,
C59 in TM1 and C252 in TM6, and replaced them with serine residues (Figure
1).  This form of the receptor, referred to as Cys–less Ste2p.FT.HT
(Cys–less), displayed biological activities (Figure 2) and pheromone binding
affinities (Table 7) indistinguishable from those of WT Ste2p and
Ste2p.FT.HT.  In all three receptors (WT Ste2p, Ste2p.FT.HT, and Cys–less
Ste2p.FT.HT), 0.4 mg of a–factor caused 17.5 mm halo size in the growth
arrest assays (Figure 2), and these GPCRs displayed Ki values between 4 and
7 nM (Table 7).  The complete tolerance of Ste2p to replacement of C59
and C252 with alanine (Martin et al. 1999) or isoleucine and alanine,
respectively (Dube et al. 2000), has been reported previously.  The
substitution of either or both of the Cys residues with Ser residues did not
result in any significant change in the number of receptors at the cell
surface (Table 7).  Cys–less Ste2p, Ste2p with two cysteines, or Ste2p with
one cysteine replaced by serine, all expressed about 9,000 receptors/cell as
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Figure 1.  Model of Ste2p Showing Regions Targeted in This Study.  Seven
transmembrane domains are labeled 1–7.  The three extracellular and intracellular
loops are labeled EL1–EL3 and IL1–IL3, respectively.  Also shown are the C–terminal
FLAG™ and His6 tags, location of mutated C59S in TM1 and C252S in TM6 (dark
circles in the respective TM domains), and the region where Cys–scanning
mutagenesis was performed over the first and third extracellular loops of Ste2p
(bold face in EL1 and EL3), which included a few residues at the boundary of the
transmembrane domain of Ste2p.
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Figure 2.  Dose–Response Curves From Growth Arrest Assays.  Paper discs were
spotted with various amounts (mg) of a–factor, as indicated on the right panel and
halo diameters were measured from plates, a representative of which is shown on
the left panel.  Amount of a–factor (mg) spotted on the disc is, 1 = 0.0625, 2 =
0.125, 3 = 0.25, 4 = 0.5, and 5 = 1.  Halo for 2 mg a–factor is not shown on the plate.
Results represent average from at least three independent experiments with a SE
of ± 0.2 mm.
Table 7.  Binding Data for WT, FT.HT and Cys Mutants of Ste2p
The data presented are mean ± SE of at least three independent experiments
performed in triplicate for competition binding assays and in quadruplicate for
saturation binding assays.
Receptor Ki (nM)c # Receptors/Celld
WT Ste2pa (5 – 7)a (4,900 – 8,000)a
Ste2p.FT.HT 4.0 ± 1.5 10,341 ± 897
C59S–Ste2p.FT.HTb 4.7 ± 1.2 9,240 ± 592
C252S–Ste2p.FT.HTb 7.5 ± 2.2 9,555 ± 698
Cys–less Ste2p.FT.HTb 5.7 ± 1.2 9,363 ± 632
a WT Ste2p binding constants and cell surface receptor levels were taken from previously
published results (Jenness et al. 1986; Blumer et al. 1988; Raths et al. 1988; Clark et al.
1994; Konopka et al. 1996; David et al. 1997; Dube and Konopka 1998).
b C59S–Ste2p.FT.HT, C252S–Ste2p.FT.HT and Cys–less Ste2p.FT.HT (C59S/C252S)
receptors were generated in the Ste2p.FT.HT background.
c Obtained from competition binding assays.  Binding of a–factor as determined by
saturation binding assays (Kd values) gave almost identical constants compared to the Ki
values.
d Obtained from saturation binding assays.
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measured by saturation binding assays.  These expression levels were in
agreement with the previously published results (Jenness et al. 1986; Blumer
et al. 1988; Raths et al. 1988; Clark et al. 1994; Konopka et al. 1996; David et
al. 1997; Dube and Konopka 1998).  Likewise, western blot analysis on
membrane preparations using FLAG™ antibody showed that Cys–less
receptor was expressed at levels similar to Ste2p.FT.HT (data not shown).
Growth Arrest Response of Cys–Scanned and Ala–Scanned EL1
Mutants–  Upon treatment with pheromone, cells containing WT Ste2p
arrest cell division in the G1 phase of the cell cycle and therefore fail to
grow on plates containing agar medium spotted with a–factor.  We assessed
the ability of all our thirty–six Cys substitution mutants (K100–Q135) to
arrest growth upon treatment with two different amounts of a–factor (0.6
and 1.2 mg, Table 8).  Most mutations did not affect the mutant receptor's
ability to arrest growth.  However, we identified five mutant receptors
(shown in bold face in Table 8) that displayed reduced or complete loss of
biological activity.  Interestingly, starting with position 102 and ending at
position 114, Cys substitution at every third residue resulted in a dramatic
defect in signaling by the mutant receptors.  Out of these five mutants,
L102C and T114C showed only partial activity, whereas the other three
mutants, N105C, S108C and Y111C, completely lost their ability to respond to
pheromone growth arrest even at a high amount of a–factor (5 mg; data not
shown).  To further investigate tolerance of this region of EL1 to mutations
other than Cys, we generated 13 Ala substitution mutants (L102–T114) and
subjected them to growth arrest assays using 0.6 and 1.2 mg a–factor (Table
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Table 8.Growth Arrest Assay Results on Cys–Scanned Ste2p EL1 Mutants (K100–Q135)
Data for mutant receptors that are defective in signaling are shown in bold face.  Results represent
average from at least three independent experiments with a SE of ± 0.2 mm.
Receptor mm Halo (0.6 mg a–factor) mm Halo (1.2 mg a–factor)
WT Ste2p 18.5 22.5
Ste2p.FT.HT 19.5 23.0
K100C 19.0 22.5
Y101C 22.0 26.0
L102C 12.5 14.5
L103C 18.5 22.5
S104C 19.5 22.5
N105Ca No Haloa No Haloa
Y106C 18.0 23.0
S107C 19.0 23.5
S108Ca No Haloa No Haloa
V109C 20.0 24.0
T110C 19.5 23.0
Y111Ca No Haloa No Haloa
A112C 19.0 23.0
L113C 19.5 23.5
T114C 10.5 12.5
G115C 20.5 24.0
F116C 18.5 22.5
P117C 20.5 24.0
Q118C 19.0 23.5
F119C 19.5 24.0
I120C 18.5 22.5
S121C 21.0 24.0
R122C 21.0 23.5
G123C 19.5 23.5
D124C 21.0 24.0
V125C 21.5 23.5
H126C 21.5 24.0
V127C 20.5 23.5
Y128C 20.0 24.0
G129C 20.0 24.0
A130C 19.0 23.0
T131C 19.5 23.5
N132C 20.0 24.0
I133C 19.5 23.0
I134C 20.5 24.0
Q135C 20.5 24.0
a Halo diameters were also measured at 5 mg a–factor, but no halos were observed for any of these
receptor mutants (data not shown).
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Table 9. Growth Arrest Assay Results on Ala–Scanned Ste2p EL1 Mutants (L102–T114)
Data for mutant receptors that are defective in signaling are shown in bold face.  Results represent
average from at least three independent experiments with a SE of ± 0.2 mm.
Receptora mm Halo
(0.6 mg a–factor)
mm Halo
(1.2 mg a–factor)
Cys–less 20.0 23.5
L102A 14.5 17.5
L103A 20.0 24.0
S104A 20.5 24.0
N105A 15.0 17.5
Y106A 20.0 23.5
S107A 21.0 24.0
S108A 12.0 16.0
V109A 18.0 22.0
T110A 21.0 25.0
Y111Ab No Halob No Halob
A112G 21.5 25.0
L113A 19.0 22.5
T114A 11.0 13.5
a Native residue at position 112 is Ala.  This position has been substituted with Gly instead of Ala.
b Halo diameters were also measured at 5 mg a–factor, but no halos were observed for this receptor
mutant (data not shown).
9).  Interestingly the same five mutants that were found defective in
signaling from analysis of Cys–scanned EL1 mutants were found to also be
defective in Ala–scanned EL1 mutants.  However, while L102A and T114A
were partially active in both Cys and Ala substitutions, N105A and S108A
were partially active in Ala substitutions as opposed to being inactive in Cys
substitutions.  Among these mutants, substitution of Y111 with either Cys or
Ala resulted in a fully inactive receptor even at the highest amount of
a–factor used (5 mg; data not shown).  The inability of Y111A in initiating
signal transduction pathway, however, was not due to lack of receptors on
the cell surface because western blot analysis on total membranes from
yeast extracts indicated that Y111A was expressed, though at reduced
levels compared to the Cys–less receptor (Figure 3).
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Figure 3.  Western Blot Analysis of Cys–less and Y111A Receptors.
Total membranes of receptors were prepared as described in Experimental
Procedures (Part II).  10% SDS–PAGE gel was loaded with 25 mg total
membrane proteins and western blot analysis was performed as described in
Part II using FLAG™ antibody.
Growth Arrest Response of Cys–Scanned EL3 Mutants–  Previous
studies on GPCRs have suggested the involvement of sixth and seventh
transmembrane domains (TM6 and TM7) in  G protein coupling and
conformational switch required for initiation of the signal transduction
pathway (Gether and Kobilka 1998).  Photoaffinity studies with Ste2p using
different Bpa–labeled a–factor analogues indicate that the modified
pheromone might be cross–linking to a site on the receptor containing the
third extracellular loop, EL3 (Henry 2002).  These studies point to the
possible involvement of EL3 in the ligand–receptor interactions.  In light of
these observations, we studied the role this region of the receptor played
on initiation of the signal transduction pathway.  For this, we generated 15
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A
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Cys substitution mutants (L264–T278) and assessed their ability to arrest
growth in the presence of two different amounts of a–factor (0.6 and 1.2 mg,
Table 10).  Among these receptors we identified two mutants (Y266C and
G273C; shown in bold face in Table 10) that were compromised in their
signaling.  While G273C displayed partial activity, Y266C completely lost its
ability to respond to pheromone growth arrest even at a high amount of
a–factor (5 mg; data not shown).  The inability of Y266C and G273C to signal
was not due to lack of receptors present on the cell surface because
western blot analysis showed that Y266C is expressed in the total
membranes prepared from yeast cell extracts (Figure 4).  The two
signaling–deficient receptors, Y266C and G273C, were also studied for their
ability to induce the reporter gene FUS1 in FUS1–lacZ assays (data not
shown; see below).  Results from these experiments corroborated those
Figure 4. Western Blot Analysis of Cys–less and Cys–Scanned EL3
Mutant Receptors.  Total membranes of receptors were prepared as
described in Experimental Procedures (Part II).  10% SDS–PAGE gel was
loaded with 20 mg total membrane proteins and western blot analysis was
performed as described in Part II using FLAG™ antibody.
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Table 10. Growth Arrest Assay Results on Cys–Scanned Ste2p
EL3 Mutants (L264–T278)
Data for mutant receptors that are defective in signaling are shown in bold face.  Results represent
the average from at least three independent experiments with S.E. ± 0.2 mm.
Receptor mm Halo
(0.6 mg a–factor)
mm Halo
(1.2 mg a–factor)
Cys–less 19.5 23.0
L264C 20.3 23.8
A265C 20.0 23.8
Y266Ca No Haloa No Haloa
S267C 20.3 23.8
L268C 19.5 23.0
K269C 18.0 21.4
P270C 18.0 21.4
N271C 18.0 21.3
Q272C 18.1 21.5
G273C 13.3 16.6
T274C 18.8 22.7
D275C 18.1 21.9
V276C 18.9 22.4
L277C 18.7 22.6
T278C 17.5 21.0
a Halo diameters were also measured at 5 mg a–factor, but no halos were observed for this receptor
mutant (data not shown).
obtained from the growth arrest assays, thereby indicating that residues
Y266 and G273 contribute to receptor activation.
Gene Induction Response of Cys–Scanned EL1 Mutants–  Signal
transduction in response to binding of a–factor to Ste2p also results in
transcriptional activation of genes involved in mating.  One of the early
genes to be activated during the latter pathway is FUS1, which is involved in
fusion of cells during conjugation.  As a measure of response to activation of
the mating signal transduction pathway, we tested the ability of twenty–two
of our Cys substitution mutants to activate a FUS1–lacZ reporter gene
construct (Figure 5).  Based on percent maximal induction, Emax (activation
obtained from a–factor at 1 X 10–6 M), most mutant receptors were able to
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Figure 5.  Maximal FUS1–lacZ Induction (%) of Several Ste2p EL1
Mutant Receptors.  Maximal induction (%) of each mutant was calculated
with respect to Cys–less receptor when induced with 1 mM a–factor.  The
labeling of the bars as to whether a mutant is active (hatched), partially
active (gray), or inactive (black) was done based on the results from growth
arrest assays.  Data represent average from two to three independent
experiments performed in duplicate with error bars representing standard
error of the mean.
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activate the FUS1–lacZ reporter gene similar to, if not better than, the
Cys–less receptor.  On the other hand, the previously identified five mutant
receptors, described as partially active or inactive based on growth arrest
assays, induced the reporter gene at greatly diminished levels.  Among
these, the two partially active mutant receptors L102C and T114C displayed
relatively higher induction levels (about 20% of the WT Ste2p) than the
three inactive mutant receptors N105C, S108C and Y111C, which were
severely compromised in their ability to signal (about 10% activity in
comparison to WT Ste2p).  The dramatic reduction in the maximum level of
induction was limited to the five mutant receptors indicated.  Cys
substitutions at residue positions neighboring these five positions did not
dramatically affect the function of the mutant receptors since they were
able to signal at near normal levels.  Interestingly, all mutant receptors
tested with FUS1–lacZ assays, including the partially active and inactive
mutant receptors, had potencies similar to the Cys–less receptor as
determined by EC50 values (Table 11).
Effect of First Extracellular Loop Cys–Replacements on Binding of
a–factor to Ste2p–  We tested nine of the mutant receptors, including the
five mutants compromised in signaling, for their ability to bind [3H]a–factor
(Figure 6).  The number of cell surface receptors for each receptor tested
was determined from saturation binding studies using whole cells, and the Ki
value was determined from competition binding studies (Table 12 and Figure
6 showing representative binding curves).  These results showed that all of
these mutant receptors had indistinguishable binding affinities as compared
to Cys–less Ste2p.  Majority of the mutant receptors, on the other hand,
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Table 11.  FUS1–lacZ Assay Data on Several Ste2p Cys–Scanned EL1 Mutants
Data for mutant receptors that are defective in signaling are shown in bold face.  The
EC50 results are expressed as mean ± SE of at least two independent experiments
performed in duplicate.
Receptora EC50 (nM)b % Maximal Inductionb
Cys-less 31 ± 4 100.0
K100C 39 ± 8 117.0
Y101C 25 ± 11 97.5
L102C 28 ± 11 22.8
L103C 25 ± 10 83.7
S104C 33 ± 5 71.4
N105C 30 ± 7 10.6
Y106C 25 ± 12 98.4
S107C 30 ± 2 77.4
S108C 46 ± 13 8.2
V109C 25 ± 9 99.3
T110C 25 ± 11 105.8
Y111C 34 ± 2 11.2
A112C 27 ± 10 113.6
L113C 60 ± 21 78.5
T114C 22 ± 13 17.6
G115C 24 ± 11 87.2
Q118C 37 ± 6 128.4
R122C 35 ± 3 131.3
V125C 31 ± 3 116.1
Y128C 42 ± 7 130.4
T131C 40 ± 9 109.4
Q135C 26 ± 12 95.8
a Cys–less receptor was generated in the Ste2p.FT.HT background.  All other receptors with
Cys substitutions were in the Cys–less Ste2p.FT.HT background.
b Determined from FUS1–lacZ assays.  Percent maximal induction (efficacy) of each mutant
was calculated with respect to Cys–less receptor when induced with the highest
concentration of a–factor (1 mM).  EC50 (potency) reflects the concentration of a–factor
required to cause half–maximal activation.
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Figure 6.  Binding Data on Representative Receptors. Panels A, C and E
show the saturation binding data for specific binding by the indicated
receptors; Panels B, D and F show the competition binding data for the same
receptors shown in Panels A, C and E, respectively.  Cys–less receptor is
shown by closed circles (l), S108C by open circles (O) and T114C by closed
triangles (s).  Results represent data from at least three independent
experiments performed in triplicate for competition binding assays, and in
quadruplicate for saturation binding assays.
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Table 12.  Binding Data on Several Ste2p Cys–Scanned EL1 Mutant Receptors
The data are presented as mean ± SE of at least three independent experiments performed in triplicate for
competition binding assays and in quadruplicate for saturation binding assays.  Data for mutant receptors that are
defective in signaling are shown in bold face.
Receptora Biological Activityb Ki (nM)c # receptors/celld
C59S/C252S (Cys-less) Fully Active 5.7 ± 1.2 9,363 ± 632
K100C Fully Active 5.4 ± 1.4 6,122 ± 212
L102C Partially Active 5.9 ± 1.1 3,917 ± 301
N105C Inactive 3.4 ± 1.8 2,720 ± 252
S108C Inactive 3.3 ± 1.2 3,968 ± 291
Y111C Inactive 4.7 ± 1.3 4,257 ± 308
T114C Partially Active 4.4 ± 0.7 1,365 ± 210
Q118C Fully Active 3.2 ± 1.3 3,855 ± 328
Y128C Fully Active 6.5 ± 1.3 Not Determined
Q135C Fully Active 2.6 ± 0.9 7,407 ± 317
a C59S/C252S (Cys–less) receptor was generated in the Ste2p.FT.HT background.  All other receptors with Cys
substitutions were in the Cys–less Ste2p.FT.HT background.
b Determined by comparing the relative halo size of mutants to that of Ste2p.FT.HT at 1.2 mg a–factor.
c Determined from competition binding assays.  Binding of a–factor as determined by saturation binding assays (Kd
values) gave almost identical constants compared to the Ki values.
d Determined from saturation binding assays.
were reduced in their expression at the cell surface as determined from
saturation binding assays (Table 12) and as corroborated by western blot
analysis (Figure 7).  For example, the Cys–less Ste2p was expressed at about
9,000 receptors/cell, whereas mutants L102C, S108C, and Y111C were
expressed at about 4,000 receptors/cell, and N105C and T114C were
expressed at about 2,000 receptors/cell.  Importantly, Q118C, a fully active
receptor, showed the greatest reduction in expression.  Nevertheless, we
were able to detect excellent ligand binding by all of these mutant receptors
regardless of their expression levels.  Previous studies have shown that
biological responses to pheromone binding were not affected greatly by a
large reduction in the amount of Ste2p at the cell surface in S. cerevisiae
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Figure 7.  Western Blot Analysis of Cys–less and Cys–scanned EL1
Mutant Receptors.  Total membranes of receptors were prepared as
described in Experimental Procedures (Part II).  10% SDS–PAGE gel was
loaded with 25 mg total membrane proteins and western blot analysis was
performed as described in Part II using FLAG™ antibody.
(Sommers 1999; Martin et al. 2002).  Cells expressing as low as 5% of the
WT Ste2p levels could display full activation of the signal transduction
pathway.
Biologically Inactive Cys–Scanned EL1 Mutant Receptors Are Not
Dominant Negative–  Previous studies had identified dominant negative
Ste2p mutants which manifested this phenotype through titration of G
protein from the WT receptor thereby interfering with the initiation of the
signal transduction pathway (Dosil et al. 1998; Leavitt et al. 1999).  We
tested whether the five mutant receptors (L102C, N105C, S108C, Y111C, and
T114C) were able to display a dominant negative effect.  We performed five
transformations of a yeast strain (LM23–3az) harboring a functional
chromosomal copy of WT STE2 with CEN–based plasmids encoding the five
Ste2p
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mutant receptors.  We selected for transformants co–expressing WT Ste2p
and the plasmid–borne mutant receptors, and assessed their ability to
interfere with the function of WT Ste2p by FUS1–lacZ reporter gene
induction assays (Figure 8).  Out of these five mutant receptors, only L102C
and T114C were able to cause a slight reduction (about 30%) in signaling by
WT Ste2p.  The other three receptors, N105C, S108C and Y111C, showed no
dominant negative effect indicating that the WT Ste2p was expressed and
fully coupled to the signal transduction pathway.  Saturation binding assays
on whole cells of each co–expressed strain showed an increase of one and a
half to two–fold in the total cell surface receptor number when compared to
WT Ste2p expression levels alone, indicating that both receptors were
expressed at similar levels (data not shown).  These results suggested that
Figure 8.  FUS1–lacZ Assays of WT Ste2p in the Presence of Partially Active and
Inactive Mutant Receptors.  Left Panel  Untransformed strain with intact chromosomal
STE2 is referred to as WT STE2 (l).  The strain transformed with the mutant receptor is
represented by "w/" followed by the name of the mutant receptor.  Symbols for the mutant
receptors transformed into the WT STE2 strain are (O) for Cys-less, (s) for N105C, (D)
for S108C, (n) for Y111C, ( ) for L102C, and (u) for T114C.  FUS1–lacZ induction (%) of
each mutant was calculated with respect to the untransformed WT STE2 strain.  Right
Panel  Maximal induction (%) is determined from the data on the left panel with the highest
concentration of a–factor (1 mM).  Results represent average from two independent
experiments performed in duplicate.
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the mutant receptors L102C and T114C were expressed and they were able
to interact with the G protein thereby titrating it away from the WT
receptor.  Conversely, the mutant receptors N105C, S108C and Y111C were
unable to interact with the G protein and/or titrate it away from the WT
receptor even though they were expressed.
Structure of EL1, the First Extracellular Loop of Ste2p–  Biological
activity and FUS1–lacZ  reporter gene induction assays allowed us to identify
five mutant receptors with diminished capacity in signaling despite full
ability to bind the a–factor pheromone.  A striking observation was the
periodicity in the positioning of these five mutations (at every third residue
in a portion of EL1) that resulted in a signaling deficient phenotype.  To
explore any structural tendency in EL1, predictions and 3–D modeling were
performed on a peptide sequence corresponding to the residues K100–L137
of Ste2p.  Since EL1 did not have significant sequence similarity to any
proteins with known structures, PROSPECT (Xu and Xu 2000) was used to
predict its structure based on fold recognition.  PROSPECT selected 1grj in
PDB (Bernstein et al. 1977) as the best template with the sequence identity
of 26.3%.  The range in the template 1grj was between residues 117 and 156.
An atomic model was built based on the alignment (Figure 9).  Although the
confidence level of the prediction was not very high (60% confidence),
modeling suggested that the N–terminal half of EL1 may contain a 310–helix
followed by a short b–sheet on the C–terminal half of the loop.
Interestingly, positions of mutations that resulted in defective signaling in
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Figure 9.  Structural Model for Ste2p EL1 Sequence Between Residues
100–137.  Amino (N) and carboxyl (C) termini are shown along with the
corresponding sequence of EL1 over which predictions were done.  C, H, and
E in the predicted structure stand for loop, a–helix, and b–strand,
respectively.  Underlined residues are positions on the loop where Cys
substitutions resulted in partial or complete loss of activity of the mutant
receptors.  The location of a possible 310–helix is shown below the predicted
structure of the loop (underlined).
Ste2p EL1 Sequence :KYLLSNYSSVTYALTGFPQFISRGDVHVYGATNIIQVL 
Predicted Structure :CCCCCCHHHHHHHHHCCHHHHCCCCEEEECCCCEEECC 
||||||||||||||||||||||||||||||||||||||
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the five mutant receptors coincided very closely with the predicted helical
region of the loop.
In order to obtain some biophysical evidence regarding the structure
of EL1 we synthesized a thirty amino acid sequence corresponding to
residues 103–132 of the loop region.  The peptide contained a non–natural
Gly residue at the carboxyl terminus to facilitate solid phase synthesis.
This peptide was found to have very low solubility in physiological buffers
and aggregated strongly in water.  We determined that solubility was
pH–dependent and increased at higher pH values.  Accordingly, we carried
out CD analysis both in mixed organic aqueous medium and water, and buffer
at pH above 8.0.
The CD spectrum of the EL1(103–132) peptide in TFE:Water [8:2
(v/v)] was characterized by minima at 222 nm and 206 nm  and a maximum at
190 nm (Figure 10).  The general shape of the spectrum was similar to those
reported for a–helical polypeptides.  However, the mean residue ellipticities
for EL1(103–132) were approximately –9700 deg–cm2–decimole–1 at 206 nm
and –6900 deg–cm2–decimole–1 near 222 nm.  These are much lower than
mean residue ellipticities reported for a–helices, and would be indicative of a
low percentage of helical structure.  A typical a–helix gives rise to two
negative bands at 208 nm and 222 nm of almost equal intensities, whereas
the corresponding bands of a typical 310–helix are of different intensities
(Toniolo et al. 1996; Formaggio et al. 2000).  Based on observation of such a
characteristic CD spectrum for EL1 in TFE/H2O (Figure 10), our CD studies
therefore suggest presence of a possible 310–helix in EL1.  When CD studies
were carried out in water at higher pH values (adjusted to pH 9.2 by using
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Figure 10.  CD Studies of a Synthetic Peptide [EL1(103–132)] Corresponding to
the First 31 Residues of the First Extracellular Loop of Ste2p.  CD studies
were carried at 26–ºC in 80%–TFE / 20% Water (l), water, pH 9.2 (O), and 50 mM
Tris, pH 8.6 (t).
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1% NH4OH), the spectrum changed significantly with the distinct minima
mentioned above changing in both position and relative intensity.  For
example the higher wavelength minimum moved from 222 nm to below 220
nm (about 205 nm).  Furthermore, the shape of the spectrum was not typical
for any regular polypeptide and would be more consistent with a mixture of
helices, b–sheet, and disordered structures.  In 50 mM Tris buffer, pH 8.6,
the peptide exhibited a CD spectrum manifesting a very broad minimum from
200–220 nm that was also indicative of a mixture of secondary structures
(Figure 10).  Overall, the CD spectra obtained in both mixed organic media
and in water at pH greater than 8 indicated that the synthetic peptide
assumed a variety of structures among which were likely helical and b–sheet
elements, where the helical content could be provided by a possible 310–helix
structure.
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CHAPTER III.  DISCUSSION
An analysis of GPCRs from different families has suggested that
peptide ligands interact with extracellular domains of receptors (Baldwin
1994; Coughlin 1994; Ji et al. 1998; Marshall 2001) unlike small GPCR ligands
that bind exclusively in a pocket formed by transmembrane domains
(Trumpp-Kallmeyer et al. 1992; Baldwin 1994).  The role of extracellular
domains in binding of peptides encouraged us to more closely investigate the
contribution of Ste2p extracellular loops to ligand binding and receptor
activation.  The rationale behind focusing on the first and third extracellular
loops, EL1 and EL3, came from studies by Sen and coworkers (Sen and Marsh
1994; Sen et al. 1997), who showed that EL1 and EL3 contained determinants
for ligand selectivity.  The second extracellular loop, EL2, was not included in
these studies because it was not found to contribute to ligand selectivity.
We therefore decided to follow a systematic, site–directed mutagenesis
analysis over the entire loop residues corresponding to EL1 and EL3 of
Ste2p.
For the systematic mutagenesis of EL1 and EL3, we decided to use the
Cys–scanning mutagenesis method, because Cys is average in bulk, highly
amenable for subsequent modification using sulfhydryl specific reagents, and
generally well–tolerated as a replacement for all amino acids in GPCRs.  When
used in conjunction with biochemical and biophysical techniques,
Cys–scanning methodology can provide valuable information on accessibility
of residues to the aqueous and lipidic environments, on spatial proximity
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between domains, and on residues near or at binding crevices that are
important for ligand interactions.  These important properties have allowed
successful use of the Cys–scanning mutagenesis method for several
membrane proteins (Frillingos et al. 1998; Javitch et al. 1999; Iwaki et al.
2000), including Ste2p (Dube et al. 2000).
In this study, we generated a library of thirty–six (K100–Q135 on EL1)
and fifteen (L264–T278 on EL3) Ste2p mutants wherein each residue of the
loop was replaced with Cys one residue at a time.  In addition to Cys
substituted EL1, we also generated a library of thirteen Ste2p mutants with
single Ala substitutions over residues L102–T114.  Since the template used in
this study was devoid of Cys each resulting Cys–scanned Ste2p mutant
receptor contained only one Cys residue.  Halo assays showed that the
majority of the Ste2p receptors with mutations of EL1 residues displayed
growth arrest indistinguishable from that of WT Ste2p (Table 8).  On the
other hand, we identified five mutations (L102C, N105C, S108C, Y111C, and
T114C) in the N–terminal portion of EL1 that caused either partial or severe
loss of biological activity of the mutant receptors.  Out of these, L102C and
T114C displayed partial activity, while N105C, S108C and Y111C completely
lost their biological activities.  When we tested twenty–two of our EL1
mutant receptors as to their proficiency to activate a FUS1–lacZ reporter
gene construct  (Figure 5), only the previously identified five mutant
receptors exhibited severely diminished capacity to transduce signal.
Mutations in neighboring receptor positions resulted in WT–like FUS1–lacZ
induction levels.  These results suggested that residues 102–114 of EL1 of
Ste2p play an important role in the function of the receptor, an observation
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that was further supported by the growth arrest assay results from
Ala–scanned EL1 mutants (Table 9).
Similarly, halo assays on Cys–scanned EL3 mutants showed that
majority of these receptors exhibited activities similar to WT Ste2p.
However, two mutant receptors with signaling–deficient phenotypes were
identified (Table 10).  Among these, Y266C was unable to activate the signal
transduction pathway while G273C could do so only partially.  These results
were further corroborated by FUS1–lacZ reporter gene induction assays on
these two mutants (data not shown).  Western blot analysis of Y266C and
G273C showed that these receptors were expressed in total membranes
(Figure 4), which suggested that lack of signaling by Y266C and diminished
signaling by G273C were not due to expression problems.  Though binding
studies were not done on Y266C, an independent study suggested that this
residue did not contribute to ligand binding properties of the receptor (Lee
et al. 2002).  As a result, our studies with Cys–scanned EL3 mutants allowed
us to identify two additional residues that were important in the
conformational change required by the receptor to reach the activated
state for initiation of the pheromone signal transduction pathway.
The compromised ability to signal observed for the five Cys–scanned
EL1 mutant receptors could result from improper folding, defective
trafficking, reduced level of cell surface expression, and/or diminished or
lost binding properties of these receptors.  To delineate the specific
reasons behind the observed signaling–deficient phenotype of these five
mutant receptors, we performed a number of experiments on whole cells
including saturation binding assays to quantify the number of cell surface
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receptors and their binding properties.  Collectively, these studies showed
that all of these five mutant receptors had WT–like binding affinities for
a–factor in spite of some diminished cell surface expression.  On the other
hand, the apparent reduction in the cell surface expression of these mutant
receptors did not correlate with the observed signaling–deficient phenotype.
Our saturation binding studies showed that T114C, a partially active
receptor, had the most dramatic reduction in cell surface expression (about
15% of Cys–less Ste2p levels), while N105C, S108C and Y111C were
expressed at higher levels (about 40% of Cys–less Ste2p levels) but were
completely inactive for signal transduction.  Also, the fully active Q118C was
expressed at levels similar to the three inactive receptors.  Furthermore, it
was previously shown that, unlike mammalian GPCRs whose function is
regulated by cell surface expression levels, yeast cells that express
anywhere from as low as 5% to as much as 20–fold excess of the normal
level of receptors can transduce signal at near normal levels (Sommers 1999;
Martin et al. 2002).  Taken together, these data indicate that the profound
signaling defect of the five mutant receptors was not connected to their
level of expression.
The five mutant receptors were able to bind a–factor with near WT
affinities, but they were unable to initiate signal transduction.  Therefore,
we concluded that these five mutations on EL1 prevented Ste2p from
assuming its activated state.  To investigate this hypothesis, we tested
effects of the five signaling–deficient mutant receptors on the function of
WT Ste2p when co–expressed in yeast cells.  Out of these five mutants, only
the partially active receptors L102C and T114C were able to moderately
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interfere with the function of WT Ste2p, while the inactive receptors
N105C, S108C and Y111C had no effect even though they were expressed at
the cell surface.  Studies with previously identified dominant negative
mutants of Ste2p concluded that the observed effects were due to the
titration of G proteins from WT Ste2p (Dosil et al. 1998; Leavitt et al.
1999).  In light of these observations, our studies with the five mutant
receptors suggested that L102C and T114C were able to interact weakly with
G protein thereby reducing its interaction with WT Ste2p, whereas N105C,
S108C and Y111C were unable to interact with G protein.  The regions of
Ste2p known to interact with G protein are the third intracellular loop (IL3)
and distal part of the C–terminal tail (Clark et al. 1994; Dosil et al. 2000).
Therefore, it is possible that the five mutations on EL1 may affect the
ability of Ste2p to attain an activated state required for coupling to G
protein to initiate signal transduction.
Interestingly, the five mutants manifesting a signaling defective
phenotype were observed at every third position of the loop starting from
residue 102 and ending at residue 114.  The observation of a distinctive
periodicity in signaling–deficient phenotype at every third position of EL1
from position 102 to 114 was provocative.  We reasoned that this region of
the loop might contain a 310–helix —a secondary structure with 3
residues/turn rather than the typical 3.6 residues/turn of a standard
a–helix.  Using PROSPECT, the region of EL1 between residues 105 and 115
was predicted to contain a 310–helix, followed by a short b–sheet region
between residues 125 and 136 of EL1.  CD studies on EL1(103–132) suggested
that this peptide displayed different structural elements depending on the
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solvent and pH of the solution used and were thus inconclusive as to the
presence of a 310–helix at the N–terminal half of EL1.  However, the
characteristic negative bands of unequal intensities at 208 nm and 222 nm
suggested presence of a possible 310–helix in EL1.  Further studies are
needed to investigate this possibility.
Previously Schwartz (Schwartz 1996) noted that despite an apparent
absence of sequence homology between GPCRs, the lengths of extracellular
and intracellular loops may be conserved, at least in the rhodopsin
superfamily of GPCRs.  When we compared extracellular loops of several
GPCRs, we noticed that in general GPCRs contain two small extracellular
loops and a third larger extracellular loop with no apparent conservation in
the loop size relative to its position in the receptor.  With this observation,
we also noted that the size of rhodopsin's EL2 was very similar to that of
Ste2p's EL1: 29 versus 30 residues, respectively.  A crystal structure of
rhodopsin in the ground state (Palczewski et al. 2000) shows that the
extracellular loops fold around two twisted b–hairpins forming a compact
domain while the N–terminal domain contributes the second pair of
b–strands.  The two highly conserved Cys residues on EL1 and in the middle
of EL2 of rhodopsin bring TM3 and TM5 together through a disulfide bond.
In this compact structure, EL2 dips into the membrane and caps the retinal
binding site.  Importantly, the stability of the activated state of rhodopsin
relies strongly on retaining its retinal at the active site by b–sheet capping
via the conserved disulfide bond between EL1 and EL2.  Though EL2 is
important for the receptor structure and folding, it is not involved in ligand
binding.  Interestingly, our studies show that analogous to EL2 of rhodopsin,
62
EL1 of Ste2p does not participate in binding of a–factor but plays a very
crucial role in the receptor activation.  Our studies also provide the first
genetic evidence that indicates EL1 of Ste2p may have a unique structural
fold wherein its first half forms a 310–helix and its second half forms a
short b–sheet structure.  Obviously, the true three–dimensional structure of
EL1 will require either direct biophysical studies on the intact receptor or
high–resolution studies on more constrained peptide fragments of this
receptor domain.
Structural analysis of extracellular loops of a few other GPCRs has
been done using solution NMR studies and a variety of other methods.  For
example, in the cholecystokinin A receptor (CCKA–R), structural studies using
portions of TM6, TM7, and the EL3 that connects them showed that this
loop has an a–helical structure and that the ligand, CCK–8, interacts with
this loop and TM6 (Giragossian and Mierke 2001).  Solution structure of
homocysteine disulfide bond constrained EL2 of human thromboxane A2
receptor (TP) showed that its EL2 contains two b–turns in the middle of the
loop (Ruan et al. 2001).  This loop was previously proposed to be involved in
ligand binding.  In another study, the structure of EL1 of angiotensin II AT1
receptor was determined using CD and fluorescence (Schreier 2001).  These
studies showed that EL1 of this receptor formed a b–turn in the middle of
the loop and this loop played an important role in ligand binding.  Finally,
using a combination of CD, fluorescence, NMR, and molecular dynamic
modeling on EL2 of k opioid receptor in DPC micelles, Zhang et al. (Zhang
2002) showed that this loop, previously proposed to be the ligand binding
site for dynorphin, is highly amphiphilic and contains a well–defined helical
63
structure and a b–turn in the middle of the loop.  Consistent with the
observations presented for EL1 of Ste2p in the present report, the studies
on these other peptide–binding GPCRs clearly demonstrate that their
extracellular loops may have distinct structural elements that are important
for either ligand binding or overall structural stabilization and proper folding
of the receptor.
Activation of GPCRs requires switching of the interhelical constraints
that stabilize the inactive state to a new set of contacts in the activated
state.  The free energy for this activation process comes from binding of
the ligand, which in turn results in activation of the G protein (Kenakin 1997;
Gether and Kobilka 1998).  Given that a signaling–deficient phenotype is
observed at five periodically located positions of the N–terminal region of
EL1, this loop of Ste2p may be important in forming part of the network of
interhelical constraints that defines the off–state of a general
transmembrane switch.
In conclusion, our studies with EL1 of Ste2p show that residues
102–114 of this loop are important in initiation of the pheromone signal
transduction pathway in yeast but not in pheromone binding itself.  In
addition residues 266 and 273 of EL3 are also important in pheromone
induced signaling by Ste2p.  To our knowledge, this is the first example of a
GPCR wherein specific residues in an extracellular loop contribute to the
ability of the receptor to initiate signaling, leading us to surmise that
specific residues of EL1 and EL3 are involved in the attainment of the
activated state of the receptor.  Further studies with these extracellular
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loops of Ste2p should bring additional insights into how this and other GPCRs
are activated.
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PART IV.  STUDIES WITH SIGNAL–DEFICIENT RECEPTOR
MUTANTS FROM CYS–SCANNED Ste2p EL1 AND EL3 IN
THE CONSTITUTIVELY–ACTIVE RECEPTOR BACKGROUND
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CHAPTER I.  INTRODUCTION
G protein–coupled receptors are complex molecules that couple
external ligand binding to the activation of the cytosolic heterotrimeric G
proteins and other effectors (Gether and Kobilka 1998; Gether 2000).
Despite the availability of a high–resolution crystal structural information on
the dark–adapted state of rhodopsin (Palczewski et al. 2000), which forms
the largest family of GPCRs, information on a detailed dynamic picture of
agonist binding has been lacking.  Several lines of evidence point to
ligand–specific conformational changes as well as the existence of
intermediate conformational states for receptors activated by a single
agonist (Gether and Kobilka 1998; Gether 2000; Liapakis et al. 2004).
Crystal structural information corresponding to various states of GPCRs,
especially in the active state, will need to be obtained for a high–resolution
snapshot of each conformation of the GPCRs.
Several disease states have been associated with aberrant functions
of peptide activated GPCRs, such as constitutive activity, loss–of–function
mutations, dominant negative effects, and expression and mislocalization
problems, to name a few (Ji et al. 1998; Schoneberg et al. 1999; Edwards et
al. 2000; George et al. 2002).  All these properties of GPCRs in turn have
rendered them as one of the largest class of membrane proteins to be
studied as drug targets (Hebert and Bouvier 1998; Schoneberg et al. 1999;
Edwards et al. 2000; Gether 2000).
The difficulty in identifying new drugs that target GPCRs may
partially reflect the inherent complexity of GPCR signaling, and the
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difficulty of identifying a link between a particular GPCR and a disease.
Insights into the complex mechanisms that govern GPCR activation will
therefore come from structures of GPCRs bound to different ligands, as
well as coupled to various G proteins.  Elucidating these delicate details will
in turn help understand the pathophysiology of many diseases and develop
GPCR ligands with greater therapeutic efficacy and fewer side effects.
Until detailed structural evidence becomes available, studies with GPCRs
containing loss–of–function, dominant negative, and constitutively activating
mutations, as well as others, will be important for determining functional
properties and relative conformations of these receptors.  Collectively, all
this information will provide a better understanding of the structural
elements that govern the mechanism of activation of GPCRs.
The budding yeast Saccharomyces cerevisiae mating pheromone
receptor Ste2p and its pheromone ligand a–factor have been used
extensively as a model system to study peptide–receptor interactions.  Over
the years, several classes of mutations have been identified in Ste2p that
conferred, among others, loss–of–function, dominant negative, and
constitutively–active receptor phenotypes.  A genetic screen designed to
isolate receptor mutations that could signal in the absence of the pheromone
ligand a–factor, resulted in identification of the constitutive P258L mutation
in the sixth transmembrane domain (TM6) of Ste2p (Konopka et al. 1996).
In two other studies, similar screens resulted in isolation of several other
constitutively–active mutant receptors, of which the strongest phenotype
was displayed by the previously identified P258L mutation (Sommers et al.
2000; Parrish et al. 2002).  Additional constitutively–active receptors were
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identified in another study where the polar residues in TM6 were targeted
(Dube and Konopka 1998).  In this (Dube and Konopka 1998) and another
(Parrish et al. 2002) study the site–directed mutagenesis approach led to
the identification of constitutively activating mutations that, when combined
with other constitutively activating mutations, no longer retained their
ability to signal in the absence of the ligand.  Genetic screening of mutations
in TM3 of Ste2p that resulted in loss of signaling allowed identification of
three mutant receptors E143K, T144P, and I142N that were defective in
signaling (Sommers and Dumont 1997).  In this same study, a second round of
mutagenesis followed by screening for mutations that could restore the
Ste2p function in the initial loss–of–signal mutations from TM3 then allowed
identification of three intragenic second–site suppressors.  One of these
suppressors was the mutant receptor Y266C that was completely defective
in signaling (Sommers and Dumont 1997).  The same mutation (Y266C) was
also isolated in Cys–scanning mutagenesis studies of TM5 and TM6 of Ste2p,
where several other mutants with either constitutively–active or defective
phenotypes were also identified (Dube et al. 2000; Lin et al. 2003).
Additional mutagenesis studies where focus was given to the extracellular
ends of the transmembrane domains of Ste2p resulted in identification of
several other mutants that were defective in signaling (Lin et al. 2004).
Finally, in an exhaustive mutagenesis study, where individual transmembrane
regions were subjected to random mutagenesis, several single, double, triple
and multiple mutations in Ste2p were obtained that conferred a variety of
phenotypes including constitutive activity and diminished signaling (Martin et
al. 2002).
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Despite the above mentioned detailed mutagenesis studies and genetic
screens on Ste2p, thus far no studies have focused on genetic screens that
were aimed at isolating mutations that suppressed constitutive signaling by
Ste2p mutants.  Our scanning mutagenesis studies on the first and third
extracellular loops, EL1 and EL3, of Ste2p allowed identification of several
mutant receptors that rendered the receptor inactive despite good ligand
binding properties (see Part III of this dissertation; also see Akal-Strader
et al. 2002).  With these defective mutants at hand, the question arose as
to what would happen when mutations that resulted in signal–deficient
receptors were combined with a mutation that rendered the receptor
constitutively–active.
In order to address this question, we decided to combine the
previously identified strong constitutively activating mutation, P258L, with
each of our single Cys EL1 and EL3 mutations that resulted in
signal–deficient phenotypes (see Part III and Akal-Strader et al. 2002).
This part of the dissertation describes our studies with the thus generated
double receptor mutants and our efforts to understand the functional
properties of these receptors.  Similar approaches, in which a constitutively
activating mutation was combined with a mutation that rendered the
receptor nonfunctional, have been applied to other GPCRs but only in a few
cases (Gaudin et al. 1999; Chen et al. 2000; Schmidt et al. 2003).  However,
to our knowledge this line of investigation has not yet been used in the
Ste2p receptor.  Here we report our simple but novel approach on Ste2p and
present our results from studies on Ste2p mutants containing two distinct
types of mutations.
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CHAPTER II.  RESULTS
Disruption of FAR1 in the LM102 Yeast Strain–  Initiation of the
pheromone–induced signal transduction pathway in yeast Saccharomyces
cerevisiae results in stimulation of a mitogen–activated protein kinase
signaling cascade that triggers the transcriptional activation of
pheromone–responsive genes and growth arrest in the G1 phase of the cell
cycle (Dohlman et al. 1991; Dohlman 2002).  Due to their ability to signal in
the absence of the added ligand, constitutively–active mutant receptors can
lead to ligand–independent cell division arrest, which can be fatal for the cell
especially if the mutant receptor displays a strong constitutive phenotype.
For studies in this part of the dissertation where the strong constitutively
activating P258L mutation was incorporated into Ste2p and signal–deficient
Ste2p mutants from EL1 and EL3, the LM102 ste2–D yeast strain was used.
However, this strain contained an intact chromosomal copy of FAR1 that
needed to be disrupted to prevent Far1p from initiating the growth arrest
response.
Disruption of the chromosomal copy of FAR1 gene was accomplished
essentially as described previously (Gueldener et al. 2002) by replacement
with the kanamycin resistance (kanr) cassette, which permitted high
efficiency selection of transformants from yeast by their resistance to the
aminoglycoside antibiotic Geneticin® (G418).  For this, the region
corresponding to the kanr cassette was PCR amplified from the plasmid pUG6
(Guldener et al. 1996) using forward and reverse gene disruption primers,
which contained homologous sequences to the ends of the FAR1 ORF and
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priming sequences to the kanr gene disruption cassette to result in the
replacement of the entire FAR1  gene locus through homologous
recombination.  PCR amplification of the kanr using these primers yielded a
fragment with the expected size of 1.7–kb (Figure 11).  The PCR products
were pooled to increase yield and the pooled product was transformed into
the LM102 cells.  Yeast transformants were then selected on YEPD plates
containing G418.  Three candidate clones, referred to as AAS01, AAS02 and
AAS03, were isolated that remained resistant to G418 after re–streaking
for isolation.
Initial detection of the correct gene disruption of the FAR1 ORF was
done by diagnostic PCR.  Genomic DNA prepared from the yeast strains
LM102, AAS01, AAS02 and AAS03 was subjected to PCR amplification using
Figure 11.  Picture of Ethidium Bromide (EtBr) Stained 1% Agarose Gel
Showing Successful PCR Amplification of the Kanamycin Cassette (kanr).  PCR
primers contained homologous sequences to the ends of the FAR1 ORF and priming
sequences to the kanr gene disruption cassette.  Lane 1 shows the 1–kb DNA ladder
with the corresponding sizes indicated to the left of the gel.  Lanes 2–8 show the
PCR products and the primer front with the corresponding sizes and locations
indicated by arrows to the right of the gel.
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forward and reverse check primers, which allowed amplification of the FAR1
ORF containing ~500–nt of its upstream and downstream sequences.  If the
FAR1 gene were knocked out the expected size of the amplified region
including the kanr cassette would be 2.270–kb.  On the other hand, if FAR1
gene were still there, the region amplified would have a larger size of
3.148–kb.  The sizes of these two PCR fragments were different enough
(~1–kb) to allow unambiguous discrimination of the FAR1 clones from the
far1::kanr clones on 1% agarose gel stained with ethidium bromide (EtBr;
Figure 12).  Out of the three candidate clones, AAS02 and AAS03 appeared
to have successfully integrated the kanr cassette into their genomes, as
judged by a shift in the size of these PCR products from ~3.1–kb to ~2.3–kb.
Figure 12.  Picture of Ethidium Bromide (EtBr) stained 1% Agarose Gel Showing
Results of Diagnostic PCR Analysis on the Three Candidate Clones.  PCR check
primers were designed ~500–nt upstream and downstream of the start and stop
codons of the FAR1 ORF.  Lane 1 shows the 1–kb DNA ladder with the
corresponding sizes indicated to the left of the gel.  Lane 2 shows the PCR
amplification pattern of the undisrupted parent LM102 strain.  Lanes 3–5 show the
PCR amplification patterns of the candidate clones 1–3, which are referred to as
AAS01–AAS03 throughout the text.  PCR Products 1 and 2, indicated by arrows to
the right of the gel, correspond to the sizes of products from the unsuccessful
(FAR1) and successfully disrupted (far1::kanr) clones, respectively.
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On the other hand, AAS01 showed a similar PCR amplification pattern as the
undisrupted parent LM102 strain, which indicated failure of the kanr
cassette in integrating into the correct locus of the genome of AAS01.
In addition to the above diagnostic PCR studies, genomic Southern
blotting analysis was also carried out to test for the correct genomic
integration of the kanr disruption cassette.  Forward and reverse probe
primers were designed to amplify the entire FAR1 ORF from the parent
strain LM102 for subsequent preparation of 32P–ATP radiolabeled probes.
These probes were then used to detect presence of FAR1 in the genomic
DNA prepared from LM102, AAS01, AAS02 and AAS03 after digesting with
two different restriction enzymes.  Digestion patterns from KpnI, which
cuts only outside the FAR1 ORF, and XbaI, which cuts both inside and
outside the FAR1 ORF, were then compared between LM102 and the three
candidate strains (Figure 13).  As previously observed by the diagnostic PCR
analysis, the genomic Southern blot analysis also revealed similar digestion
patterns for AAS01 and the parent LM102 strain, further corroborating the
failure in the integration of kanr into the genome of AAS01.  Different
patterns of digestion observed in AAS02 and AAS03 suggested that the
kanr cassette was most likely integrated into the correct locus in their
genome, as previously implicated in the diagnostic PCR analysis.
Another assessment for the correct FAR1 disruption came from
biological studies in which LM102, AAS01, AAS02 and AASO3 were
transformed with a plasmid encoding the wild–type Ste2p receptor.  Growth
arrest assays using 1 mg a–factor resulted in formation of similarly large
sized halos in both LM102 and AAS01 (data not shown), indicating that the
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Figure 13.  Results From Genomic Southern Blotting Analysis of the Candidate
Strains.  Genomic DNA digests were run on 0.7% agarose gel and transferred to
nitrocellulose membrane.  Radiolabeled fragments were detected by exposure to a
phosphorimager screen.  Digestion patterns of the candidate strains were visually
compared to those of the LM102 parent strain after digesting with KpnI and XbaI.
Candidates 1–3 are referred to as AAS01–AAS03 throughout the text.
kanr gene disruption cassette was not integrated into the FAR1 locus in
AAS01.  On the other hand, similar analysis resulted in formation of a halo in
AAS03 that was half the size of that seen in LM102 and AAS01, suggesting
that the FAR1 locus was not efficiently disrupted in AAS03, which resulted
in the observed leaky FAR1 phenotype (data not shown).  Complete lack of
halo formation was observed in AAS02, however, which confirmed the
successful knock–out of FAR1 by replacement with the kanr cassette.  Since
affirmative confirmation for the successful far1::kanr disruption was
unambiguously established for AAS02 by means of all the diagnostic tests,
this strain was used as the recipient host strain for transformation of the
Ste2p and Ste2p mutants containing a constitutively activating mutation.
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Construction of a Functional P258L–Ste2p–  The P258L mutation was
previously identified in two different genetic screens as a strong
constitutively activating mutation that could initiate the pheromone signal
tranduction pathway in a ligand independent manner (Konopka et al. 1996;
Sommers et al. 2000).  Though several other strong constitutive mutants
were isolated from these screens, as a result of its robust constitutive
phenotype, P258L was favored as the candidate constitutively activating
mutation to incorporate into the defective mutants from EL1 and EL3.  Prior
to construction of these double mutant receptors, however, we wanted to
test the functionality of the single P258L mutant receptor and confirm that
its properties matched those obtained previously in the literature.
In former studies, P258L mutant receptor was found to display about
6–fold to 7–fold higher basal activity in the absence of the a–factor
pheromone as compared to the wild–type receptor (Sommers et al. 2000).  In
addition, P258L could also be activated completely at concentrations of
a–factor similar to those required to fully activate the wild–type receptor
(Sommers et al. 2000).  Another feature of the P258L mutant was its higher
sensitivity to a–factor in FUS1–lacZ gene induction assays when compared to
the wild–type receptors (Sommers et al. 2000).
The Cys–less Ste2p.FT.HT construct stably expresses Ste2p from its
native promoter, has both of its native Cys residues substituted with Ser,
and contains C–terminal FLAG™ and His6 epitope tags (see Part III of this
dissertation).  This form of the receptor was found to maintain similar
activity and binding properties as the wild–type receptor, and was therefore
successfully used as the template for mutagenesis of Ste2p throughout the
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studies described in this dissertation.  As a result, this construct was used
as the template to incorporate the P258L mutation.  The thus generated
P258L Cys–less Ste2p.FT.HT mutant was transformed into the above
described AAS02 yeast strain (see FAR1 disruption) and its activity was
determined using the pheromone–inducible FUS1–lacZ reporter gene.  The
dose–response curves for the Cys–less Ste2p.FT.HT and P258L Cys–less
Ste2p.FT.HT are shown in Figure 14.  These results clearly showed that the
P258L mutant was unable to display constitutive activity in the absence of
the ligand, as judged by the absence of elevated basal activity at 1 X 10–11 M
a–factor concentration compared to the wild–type.  Furthermore, it was not
fully activatable even in the presence of saturating amounts of a–factor (1 X
10–6 M).  Finally, the dose–response curve of P258L was shifted rightward
Figure 14.  Dose–Response Curves for Cys–less Ste2p.FT.HT and P258L Cys–less
Ste2p.FT.HT.  Dose–response of mutants was determined by FUS1–lacZ gene induction
assays.  Relative responses were expressed as % of activity with respect to Cys–less
Ste2p.FT.HT.  Gene induction assays were performed in the AAS02 (ste2-D far1::kanr)
strain.  EC50 (potency) is the concentration of a–factor required to give half–maximal
activation.  Fold basal activity was calculated by taking the ratio of the induction for P258L
mutant to that of the Cys–less receptor at 1 X 10–11 M a –factor concentration.  Basal
activity of Cys–less was normalized to 1–fold.
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compared to that of Cys–less indicating that its potency (EC50; concentration
of a–factor required to give half–maximal activation) was reduced
significantly (~25 X 10–8 M for P258L Cys–less Ste2p.FT.HT mutant versus
~8.1 X 10–8 M for Cys–less Ste2p.FT.HT) rather than being increased as
would have been expected from a tighter binding.  The P258L mutation
probably results in a loss of a kink in the structure of the sixth
transmembrane domain, which upon combination with the C–terminal FLAG™
and His6 tags becomes deleterious for the function of the receptor.
Since the P258L mutant in the Cys–less Ste2p.FT.HT construct did
not display the characteristics of the previously identified P258L mutant
the same mutation was generated in the Cys–less Ste2p receptor
background.  This construct is the same as the Cys–less Ste2p.FT.HT
construct with the exception that it lacks the C–terminal FLAG™ and His6
epitope tags.  Similar analysis of the Cys–less Ste2p and P258L Cys–less
Ste2p showed that this mutant was functional and it displayed similar
properties as those observed previously (Figure 15; Sommers et al. 2000).
In the absence of a–factor (1 X 10–9 M), the basal activity of P258L Cys–less
Ste2p was ~7–fold higher than that for the Cys–less Ste2p.  At this
concentration, basal activity values were ~1% for the LM102 and AAS02
yeast host strains; ~1.7% for Cys–less Ste2p; and ~12% for P258L Cys–less
Ste2p.  Full activity could be attained in both receptors at high enough
concentrations of a–factor (1 X 10–5 M), and the P258L mutant responded to
a–factor with higher potency (EC50 of ~15 X 10–8 M) than Cys–less Ste2p
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Figure 15.  Dose–Response Curves for Cys–less Ste2p and P258L Cys–less Ste2p.
Dose–response of mutants was determined by FUS1–lacZ gene induction assays.  Relative
responses were expressed as % of activity with respect to Cys–less Ste2p.  Gene induction
assays were performed in the AAS02 (ste2-D far1::kanr) strain.  Induction of the parent
LM102 (ste2-D) strain is also included in these assays for comparison with that of the
AAS02 strain.  EC50 (potency) is the concentration of a–factor required to give
half–maximal activation.  Fold basal activity was calculated by taking the ratio of the
induction for the P258L mutant to that of the Cys–less receptor at 1 X 10–9 M a–factor
concentration.  Basal activity of Cys–less was normalized to 1–fold.
(EC50 of ~36 X 10–8 M).  All these properties rendered P258L Cys–less Ste2p
as the suitable construct for introduction of additional mutations.
Introduction of Mutations Causing Signal–Deficient Phenotypes into
P258L Cys–less Ste2p–  Single Cys substitutions on EL1 and EL3 that
resulted in signal–deficient receptor phenotypes were individually combined
with the P258L mutation in the Cys–less Ste2p receptor background.  The
thus generated double receptor mutants were transformed into the AAS02
(ste2-D far1::kanr) yeast host strain that was a modified version of the
LM102 (ste2-D) parent yeast strain.  The mutant receptors were analyzed
using pheromone inducible reporter gene assays both in the presence and
absence of a–factor (see below).  For convenience the P258L Cys–less Ste2p
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mutant receptor will be referred to as P258L, and the Cys–less Ste2p
receptor as Cys–less.  For simplicity, double mutants containing the P258L
mutation and a single Cys inactive substitution on EL1 and EL3 will be
referred to as EL1–Inactive/P258L and EL3–Inactive/P258L, respectively.
In addition to the above mutations from EL1 and EL3 that resulted in
defective receptors, several single Cys substitutions from EL1 and EL3, that
previously did not affect function of the receptor, were also combined with
the P258L mutation for control purposes.  These double mutant receptors
were referred to as EL1–Active/P258L and EL3–Active/P258L (see below).
Determination of Constitutive Responses by the Double Receptor
Mutants Combining Signal–Deficient Cys Substitution on EL1 and EL3 with
P258L–  Results from FUS1–lacZ reporter gene induction assays carried out
in the absence of a–factor indicated that all of our double mutants were
constitutively active (Figure 16) and this was evident by distinguishable
differences in their elevated basal activities when compared with the
Cys–less receptor.  In these studies, P258L displayed 6.9–fold increase in
basal activity as expected, while all the double mutant receptors displayed
basal activities that were intermediate between those for the Cys–less and
P258L receptors.  Among these, L102C/P258L, Y111C/P258L and
G273C/P258L displayed higher basal activity (3.3–fold, 3.7–fold, and
3.6–fold, respectively) than N105C/P258L, S108C/P258L, T114C/P258L and
Y266C/P258L, which displayed relative basal activities in the range of
1.9–fold to 2.5–fold.  There was not a noticeable difference in the
constitutive responses of mutants from EL1 and EL3, since mutant receptors
from both loop regions displayed similar constitutive responses.  The
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Figure 16.  Fold Basal Activity of Single and Double Receptor Mutants From EL1 and
EL3 Before and After Addition of the P258L Mutation.  Basal activity was obtained from
FUS1–lacZ gene induction assays performed in the absence of a–factor.  Relative fold basal
activity was determined with respect to the Cys–less receptor.  Hatched and solid bars
represent basal activities before and after the addition of the P258L mutation,
respectively.  Basal activity of Cys–less was normalized to 1–fold.
observed elevated basal activities by the double mutant receptors were due
exclusively to the addition of the P258L mutation in that the single
substituted signal–deficient mutants from EL1 and EL3 alone displayed
similar basal activities as the Cys–less receptor in the absence of this
mutation (Figure 16).  These results suggested that single Cys substitutions
on specific positions of EL1 and EL3 cause partial suppression of the P258L
mutation.
Gene Induction Response of the Double Receptor Mutants
EL1–Inactive/P258L and EL3–Inactive/P258L–  In the previous section,
FUS1–lacZ reporter gene induction assays in the absence of a–factor
showed that all of the double receptor mutants containing the P258L
mutation exhibited elevated basal activities compared to the single
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mutations from EL1 and EL3.  These results were supportive of a more active
conformation for the double mutants when compared with their single
mutant counterparts.  In order to assess the level of activity by these
double receptor mutants in the presence of P258L mutation, gene induction
assays were carried out over a range of a–factor concentrations.
Dose–response curves for EL1–Inactive/P258L double mutants clearly
showed that these mutants were able to signal in a ligand–independent
manner (Figure 17).  However, maximal activation of these mutants after
incorporation of the P258L mutation was negligible in most receptors (Figure
17 and Table 13).  Out of the five EL1–Inactive/P258L double mutants,
Y111C/P258L displayed a slightly increased (~2–fold higher) efficacy (Emax,
concentration of a–factor required to induce maximal response) compared to
the other mutants at the highest concentration of a–factor used (1 X 10–5
Figure 17.  Dose–Response Curves for EL1–Inactive/P258L Double Receptor
Mutants.  Dose–response of mutants was determined by FUS1–lacZ gene induction
assays.  Relative responses were expressed as % of activity with respect to
Cys–less Ste2p.  Gene induction assays were performed in the AAS02 (ste2-D
far1::kanr) strain.  Fold basal activity was calculated by taking the ratio of the
induction for the mutant receptor to that of the Cys–less Ste2p at 1 X 10–9 M
a–factor concentration.  Basal activity of Cys–less was normalized to 1–fold.
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Table 13.  Pharmacological Properties of the Double Mutant Receptors Before
and After Incorporation of the P258L Mutation
Data for mutant receptors that are defective in signaling before and/or after P258L mutation are
shown in bold face.  The EC50 results are expressed as mean ± SE of at least two independent
experiments performed in duplicate.
Receptora Fold Basal
Activityb
Fold Basal
Activity
with P258Lc
EC50 (10–8 M)
with P258Ld
% Emaxe
% Emax
with P258Lf
Cys–less 1 6.9 35.6 ± 1.5 100 100
P258L 1 6.9 15.4 ± 0.9 100 100
L102C 1.1 3.3 31.8 ± 1.3 23 21
N105C 1.2 2.2 39.0 ± 1.8 11 12
S107C 1.1 10 20.0 ± 0.9 95 113
S108C 1.1 2.5 36.0 ± 2.1 8 12
T110C 1.2 11 22.0 ± 0.9 104 107
Y111C 0.9 3.7 40.0 ± 1.7 12 23
T114C 1.2 1.9 38.1 ± 2.1 18 9
Y266C 0.9 1.8 48.0 ± 2.8 5 8
S267C 1.2 13 19.3 ± 0.4 104 101
N271C 1.1 11 21.7 ± 0.9 95 97
G273C 1.2 3.6 28.5 ± 1.0 60 54
a All mutant receptors were generated in the Cys–less Ste2p background.
b Determined from FUS1–lacZ assays before incorporation of the P258L mutation.  Fold basal activity
was calculated by taking the ratio of the FUS1–lacZ induction for the mutant receptor to that of the
Cys–less Ste2p in the absence of a–factor (1 X 10–9 M concentration).  Basal activity of the Cys–less
receptor was normalized to 1–fold.
c Fold basal activity determined after incorporation of the P258L mutation.  Calculations were done
same as in "b".
d Determined from FUS1–lacZ assays after incorporation of the P258L mutation; values before
incorporation of this mutation were similar to the Cys–less receptor.  EC50 (potency) reflects the
concentration of a–factor required to cause half–maximal activation.  EC50 values of mutants before
incorporation of the P258L mutation were similar to the Cys–less receptor.
e Determined from FUS1–lacZ assays before incorporation of the P258L mutation.  Emax (efficacy)
reflects the concentration of a–factor required to cause maximal induction.  Percent maximal
induction (% Emax) of each mutant was normalized to the Cys–less receptor when induced with the
highest concentration of a–factor (10 mM).
f Determined from FUS1–lacZ assays after incorporation of the P258L mutation.  Calculations were
done same as in "e".
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M, Table 13).  Regardless, none of these changes were comparable to the
activation of Cys–less receptor at 1 X 10–5 M concentration of a–factor,
indicating that these mutants were activated only slightly with still partially
active conformations intermediate between single and double mutant forms.
FUS1–lacZ gene induction studies on the EL3–Inactive/P258L double
mutant receptors gave results similar to those observed from studies with
EL1–Inactive/P258L mutants (Figure 18).  Dose–response curves of the
EL3–Inactive/P258L mutants also clearly showed that these receptors were
able to signal in the absence of a–factor (1 X 10–9 M).  The fold basal activity
of these mutants was between that of the Cys–less receptor and the P258L
mutant, and like the EL1–Inactive/P258L mutants, these mutants could not
be fully activated (low efficacies compared to Cys–less) at the highest
concentration of the a–factor used (1 X 10–5 M; Table 13).  In addition, the
Figure 18.  Dose–Response Curves for EL3–Inactive/P258L Double Receptor
Mutants.  Dose–response of mutants was determined by FUS1–lacZ gene induction
assays.  Relative responses were expressed as % of activity with respect to
Cys–less Ste2p.  Gene induction assays were performed in the AAS02 (ste2-D
far1::kanr) strain.  Fold basal activity was calculated by taking the ratio of the
induction for the mutant receptor to that of the Cys–less Ste2p at 1 X 10–9 M
a–factor concentration.  Basal activity of Cys–less was normalized to 1–fold.
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potencies (EC50) of both the EL1–Inactive/P258L and EL3–Inactive/P258L
mutants resembled that of the Cys–less receptor rather than the P258L
mutant (Table 13), suggesting that their phenotypes partially overcame the
effect of the P258L mutation.  Collectively, the gene induction assays on the
EL1–Inactive/P258L and EL3–Inactive/P258L suggested that these mutant
receptors were partially constitutively–active, and the double mutants
attained intermediate conformations between their single Cys substituted
counterparts and the P258L mutant alone.  The observed intermediate
phenotypes were also unique and intrinsic to these double mutants.  Control
mutants (EL1–Active/P258L and EL3–Active/P258L) generated by combining
the P258L mutation with single Cys substitutions on EL1 and EL3 that did not
affect the function of the receptor were even more constitutively–active
than the P258L mutant alone (Figure 19; Table 13).  In addition, they had
Figure 19.  Dose–Response Curves for EL1– and EL3–Active/P258L Double Receptor
Mutants.  Dose–response of mutants was determined by FUS1–lacZ gene induction assays.
Relative responses were expressed as % of activity with respect to Cys–less Ste2p.  Gene
induction assays were performed in the AAS02 (ste2-D far1::kanr) strain.  Fold basal
activity was calculated by taking the ratio of the induction for the mutant receptor to that
of the Cys–less Ste2p at 1 X 10–9 M a–factor concentration.  Basal activity of Cys–less was
normalized to 1–fold.
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higher potencies (EC50) than the Cys–less receptor, which resembled that of
the P258L mutant rather than the Cys–less receptor (leftward shift in their
dose–response curves).  They were also completely activated at a–factor
concentrations that were sufficient to fully induce the Cys–less receptor (1
X 10–5 M; Table 13).  Together, observations from gene induction studies
both in the presence and absence of a–factor supported the previously
noted importance of the signal–deficient mutant receptors from EL1 and EL3
in the activation of the receptor.
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CHAPTER III.  DISCUSSION
Cys–scanning mutagenesis studies on the first and third extracellular
loops, EL1 and EL3, of Ste2p allowed identification of several mutant
receptors with signal–deficient receptor phenotypes (L102C, N105C, S108C,
Y111C and T114C from EL1, and Y266C and G273C from EL3).  Additional
studies on these loop residues, the details of which are discussed elsewhere
(see Part III of this dissertation), pointed to the specific roles these loop
residues played in the activation of Ste2p.  In order to provide greater
insights into the key roles played by residues of EL1 and EL3 in receptor
signaling, we wanted to investigate the functional properties of the
signal–deficient mutant receptors from these loops in the presence of a
mutation that could constitutively activate the receptor.  To narrow the
decision to the most likely candidates for such a mutation, we focused our
attention on those mutations that could result in strong constitutive
signaling by Ste2p.
As one of the G protein–coupled pheromone receptors of yeast Ste2p
has been used extensively as a model receptor to study GPCR function.  The
vast trove of information that has become available over the years through a
considerable body of work on Ste2p has allowed identification of regions of
Ste2p that are important in ligand–independent signaling.  Most residue
mutations that resulted in strong constitutive signaling mapped to the sixth
transmembrane domain (TM6) of Ste2p (Konopka et al. 1996; Dube and
Konopka 1998; Sommers et al. 2000).  Among these P258L, Q253L and
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S259P mutant receptors showed robust ligand–independent activity.  Since
the strongest constitutively active receptor phenotype to be conferred by a
single substitution in Ste2p was provided by the P258L mutation, we have
decided to combine mutations from EL1 and EL3 that resulted in
signal–deficient phenotypes with this mutation.
Constitutively–active mutant receptors are identified by their ability
to display increased basal activity in the absence of their agonist ligand.  In
yeast, elevated basal activity is synonymous to cell death because one of the
outcomes of activation of the pheromone signal transduction pathway is
growth arrest in the G1 phase of the cell division cycle.  To eliminate the
possibility that mutants bearing constitutive signaling properties could cause
cell death, we modified our yeast host strain so that Far1p, upon which there
is an absolute requirement for a functional growth arrest response in yeast
cells, would no longer be able to perform its function (Chang and Herskowitz
1990).  We knocked–out FAR1 by replacing its chromosomal locus with a
kanamycin resistance (kanr) cassette.
Three candidate clones (AAS01, AAS02 and AAS03) showed
resistance to the antibiotic geneticin® (G418) which indicated that the kanr
cassette was integrated into their genomes.  Results from diagnostic PCR
analysis (Figure 12) and genomic Southern blot (Figure 13) narrowed the
number of strains that successfully integrated the kanr cassette at or near
the intended FAR1 locus down to two strains.  A final confirmation for the
complete disruption of the FAR1 locus by kanr cassette came from growth
arrest assays on each candidate strain after transformation with a plasmid
bearing a wild–type Ste2p receptor.  Out of the three strains, only AAS02
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passed all the diagnostic tests, while also maintaining its inability to arrest
growth, as indicated by lack of halo formation in growth arrest assays due to
inactive Far1p (data not shown).  Therefore, AAS02 (ste2-D far1::kanr) was
used as the recipient strain for transformation with Ste2p mutants
harboring the constitutively activating P258L mutation.  However, this means
that the growth arrest assay can no longer be used as a method of
determining activities of mutant receptors.  Therefore, biological activity
measurements were done by gene induction assays using the pheromone
responsive FUS1–lacZ reporter gene construct.
Prior to combining the P258L mutation with the mutations from EL1
and EL3, we wanted to obtain a P258L mutant receptor with functional
characteristics of that reported earlier (Sommers et al. 2000).  Our choice
of construct in which to create the P258L mutation was Cys–less
Ste2p.FT.HT, which stably expressed Ste2p under its native promoter, had
both of its native Cys residues removed, and contained C–terminal FLAG™
and His6 tags.  None of these alterations affected the function of the
receptor and, as such, this form of the receptor served as a good construct
to create additional mutations on Ste2p for use in Part III and Part V of
this dissertation.  To our dismay, this form of the receptor resulted in a
P258L mutant with aberrant characteristics, such as complete lack of
elevated basal activity in the absence of a–factor; inability to be fully
induced in the presence of a–factor; and the significant rightward shift in
the dose of a–factor required to achieve half–maximal activation (EC50),
indicating decreased sensitivity (potency) to a–factor (Figure 14).  On the
other hand, when the same mutation was incorporated into the Cys–less
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Ste2p construct in which the C–terminal tags were eliminated, a fully
functional, constitutively active mutant was obtained (Figure 15).
The P258L Cys–less Ste2p mutant receptor displayed ~7–fold increase
in its basal activity, indicative of constitutive signaling; could be fully
activated to the wild–type levels; and showed increased sensitivity to
a–factor, as judged by its lower EC50 value compared to the Cys–less Ste2p
receptor (Table 13).  All these properties of P258L Cys–less Ste2p, which
we will refer to as P258L in the remaining part of this discussion, were
reproducible and in good agreement with the previously characterized P258L
mutant receptor (Sommers et al. 2000).  Therefore, it served as a suitable
template for incorporation of the single Cys substitutions from EL1 and EL3
that previously led to defective signaling in Ste2p.  For the sake of
simplicity, the thus generated double mutants containing a constitutively
activating P258L mutation and an additional inactivating single Cys
substitution on EL1 and EL3 will be referred to as EL1–Inactive/P258L and
EL3–Inactive/P258L, respectively.  Analogously, double mutants generated
by combining the P258L mutation with single Cys substitutions on EL1 and
EL3 that previously did not affect the receptor function, will be referred to
as EL1–Active/P258L and EL3–Active/P258L, respectively.
In order to determine functional properties of these double mutant
receptors, we subjected the EL1–Inactive/P258L and EL3–Inactive/P258L
double mutant receptors to FUS1–lacZ reporter gene induction assays in the
absence of a–factor.  If combining P258L mutation with the single Cys
substitutions from EL1 and EL3 could now render the signal–deficient EL1
and EL3 mutants more active, then the double mutants, we reasoned, would
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display elevated basal activity in the absence of a–factor.  Consistent with
this interpretation was the observed increase in the basal activity of all our
double mutants when compared to that of the Cys–less Ste2p (Cys–less for
short; Figure 16).  While P258L displayed ~7–fold increase in its basal
activity, the increase in basal activity of the double mutants ranged from
1.9–fold to 3.7–fold.  Observed elevation in the basal activities of double
mutants could be ascribed entirely to the incorporation of the P258L
mutation in that none of their single Cys substituted counterparts displayed
basal activities that were different than the Cys–less receptor prior to
addition of this mutation (Figure 16 and Table 13).
Considering that residues of EL1 and EL3 form distinct regions of the
receptor that are far apart in the primary sequence of Ste2p, residues from
EL1 and EL3 might be expected to play distinct roles in receptor signaling.
If this were the case, these differences should be uncovered in the above
studies with EL1– and EL3–Inactive/P258L double mutants.  Interestingly,
however, the double mutants from EL1 and EL3 were not distinguishable
from one another in terms of their level of ligand–independent signaling.
This could suggest a common role for EL1 and EL3 residues in the regulation
of receptor signaling.
Our analysis of EL1– and EL3–Inactive/P258L double mutants revealed
that all of these mutant receptors displayed partial constitutive activity
that was between the basal activities of the Cys–less receptor and the
P258L mutant alone.  If any one of these mutations (inactivating or
constitutively activating) were to dominate over the phenotype of the other,
then dose–response studies in the presence of varying concentrations of
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a–factor should reveal this.  In order to investigate this property of the
individual mutations, we analyzed our double mutants further by assaying
their ability to signal in a ligand–dependent manner.  Interestingly though,
none of the double mutant receptors could be induced to the levels of P258L
and Cys–less receptors even at saturating concentrations of a–factor
(Figures 17 and 18; Table 13).  While there was a slight increase in the
maximal activation of Y111C/P258L (12% to 23%), this increase was nowhere
near the level of activation by P258L and Cys–less (compare the Emax values
before and after addition of the P258L mutation in Table 13).  In addition,
the observed phenotypes for EL1–Inactive/P258L and EL3–Inactive/P258L
double mutants were unique to defective mutants from EL1 and EL3 only.
This was based on the observation that fully active and fully constitutively
active mutants were obtained after combining the P258L mutation with
mutations from EL1 and EL3 that had no effect on the receptor function
(EL1–Active/P258L and EL3–Active/P258L double mutants; Figure 19 and
Table 13).  Furthermore, all of these double receptors displayed a
noticeable leftward shift in their dose–response curves indicating an
increase in their sensitivity (potency) to a–factor, which is a hallmark of
constitutively–active mutant receptors.  These observations excluded the
possibility that any substitution on EL1 and EL3, when combined with the
P258L mutation, could result in a receptor with signal–deficient phenotype.
Impaired signaling activity observed in the EL1–Inactive/P258L and
EL3–Inactive/P258L double mutants may be due either to a defect in their
receptor signaling or to a decrease in the number of cell–surface receptors
as a result of their mislocalization away from the plasma membrane.  The
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latter possibility has been demonstrated previously for other
constitutively–active Ste2p mutants (Dube and Konopka 1998; Stefan et al.
1998).  Consistent with the possibility of mislocalization of our double
mutants, we were unable to detect a–factor binding by these mutants in
radioligand binding assays on whole cells.  This kind of problem has been
previously encountered by other research groups as well.  A previous study
had similar difficulties in detecting a–factor binding to P258L mutant in
radioligand whole cell binding assays (Sommers et al. 2000).  Aside from
binding studies, we were also unable to determine expression profiles of
these double mutant receptors due to absence of an epitope tag on Ste2p
with which to follow receptors on western blots.  Therefore,
notwithstanding the lack of data on cell surface expression of the double
mutant receptors, diminished cell–surface localization of the double mutant
receptors could also contribute to defects in their ability to respond to
a–factor in gene induction assays.  However, this possibility will need to be
addressed by other methods, such as localization studies or incorporation of
another epitope tag onto these receptors that is compatible with the P258L
mutation.
Our results from ligand–independent and ligand–dependent signaling
studies on EL1– and EL3–Inactive/P258L double receptor mutants showed
that they could signal in the absence of a–factor, indicative of a more
activated conformation; however, they were unable to reach full activity,
indicative of a conformation less active than P258L.  These phenotypes were
different than those of the single, Cys–substituted, signal–deficient mutants
from the corresponding loops, which were still unable to reach full activation
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but displayed no basal signaling.  P258L mutant displayed a strong
constitutive signaling and could be activated fully, however it needed
a–factor to do so, indicating that P258L mutant did not attain a fully active
conformation in the absence of a–factor.  Taken together, these
observations support the possibility that EL1– and EL3–Inactive/P258L
double mutant receptors could assume intermediate conformations that are
in a more active state than their single Cys substituted EL1 and EL3
counterparts, but less active than the partially active P258L mutant.  This
implies that distinct conformational states may exist for the activation of
Ste2p upon binding of a–factor.  Indeed, the existence of ligand–specific
conformational changes as well as ligand–independent intermediate
conformational states for receptors activated by a single agonist have been
proposed previously for several receptors (Gether and Kobilka 1998; Gether
2000; Liapakis et al. 2004; Kobilka 2004).
In conclusion, our studies suggest that mutations on EL1 and EL3 that
cause signal–deficient receptor phenotypes, when combined with the
constitutively activating P258L mutation, partially suppress the phenotype
caused by P258L mutation alone.  This conclusion is made in keeping with the
observation that combined double mutants from EL1 and EL3 decreased the
elevated basal activity of P258L from ~7–fold down to between 1.9–fold to
3.7–fold activity over Cys–less receptor in ligand–independent gene induction
assays (Figure 16).  These findings further corroborate the previously
postulated important roles of EL1 and EL3 residues in activation of the
Ste2p receptor.  Interestingly, our earlier studies on Cys–scanned EL1
mutants have proposed that residues on one face of a 310–helix played a role
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in the conformational change required to activate the receptor (see Part III
of this dissertation).  Our studies with the EL1– and EL3–Inactive/P258L
double receptors also support this notion because residues S107 and T110,
which presumably lie on the opposite face of the same 310–helix, upon
substitution with Cys result in fully functional receptors.  Similarly, they do
not suppress the phenotype caused by the P258L mutation in their
corresponding double mutants S107C/P258L and T110C/P258L in gene
induction assays.  Conversely, residues S108 and Y111, which are proposed to
lie on the same face of the 310–helix, not only result in defective receptors
upon substitution with Cys, but also partially suppress the phenotype of
P258L in their corresponding double mutants S108C/P258L and
Y111C/P258L.
Interestingly, the EL1–Active/P258L (S107C/P258L, T110C/P258L)
and EL3–Active/P258L (S267C/P258L, N271C/P258L) mutant receptors
displayed basal activities that were even more elevated than that of the
P258L mutant alone.  The improved basal activities of these double mutant
receptors may indicate that individually the single Cys substituted mutants
(S107C, T110C, S267C and N271C) may be involved in stabilizing an active
conformation of the Ste2p receptor.  Upon combining these single Cys
substitutions with the constitutively activating P258L mutation, the
resultant double mutant receptors may now assume an even more active
conformation that could mimic a ligand–bound and ligand–stabilized receptor
conformation intermediate between the fully active and inactive states.
The observations made in the studies presented herewith have
important implications.  They corroborate the previously noted importance
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of the extracellular loop residues in signaling function of the Ste2p
receptor.  Interestingly, the EL1 and EL3 residues reside on important
regions of the receptor: EL1 connects to TM3, while EL3 connects to TM6 of
Ste2p.  These transmembrane domains are of particular interest because
they are thought to play a critical role in regulating the activity of many
GPCRs (Gether 2000).  Indeed, several lines of evidence indicate that
disruption of the interactions between TM3 and other TMs allows for motion
between TM3 and TM6, which is critical for activation of many GPCRs
(Baldwin 1994; Gether 2000).  For example, engineering binary metal ion
binding sites (Sheikh et al. 1999) as well as engineered disulfide linkages
(Farrens et al. 1996) between TM3 and TM6 prevent ligand–mediated
activation of several GPCRs.  In close agreement with these observations,
the importance of regions of TM3 and TM6 near the cytosolic end of the
transmembrane bundle in signaling of Ste2p receptor has been shown
through detailed mutagenesis analysis of specific residues on these
transmembrane domains (Parrish et al. 2002).
Activation of GPCRs requires switching of the interhelical constraints
that stabilize the inactive state to a new set of contacts in the activated
state.  Given that a signaling–deficient phenotype is observed at five
periodically located positions of the N–terminal region of EL1 and two
positions on EL3, these loops of Ste2p may be important in forming part of
the network of interhelical constraints that defines the off–state of a
general transmembrane switch.  Consistent with the key role that TM3 and
TM6 may play on receptor signaling, the residues of EL1 and EL3 underscore
the sensitivity of these loop regions to perturbations, and further indicate
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that contacts made between these residues and the remaining parts of
Ste2p may be important for the function of the a–factor receptor.  These
loops may have a conformationally sensitive switch that may regulate entry
of the Ste2p receptor into its activated conformation.  Mutations on these
loop residues may trigger the disruption of hydrogen bonding interactions
between the loop residues and their specific contact sites, preventing the
receptor from isomerizing into its active state.  Thus, despite lack of
sequence homology between Ste2p and other GPCRs, and the absence in
Ste2p of several conserved residues found in other families of GPCRs, these
receptors may perform their function using similar mechanisms of activation.
97
PART V.  TESTING PREDICTED INTERACTIONS BETWEEN
RESIDUES IN THE TRANSMEMBRANE REGION OF Ste2p
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CHAPTER I.  INTRODUCTION
Direct structural analysis of GPCRs using traditional crystallographic
methods has been relatively unfruitful due to their highly hydrophobic
nature, difficulties in obtaining large amounts of the purified proteins and
solubilization for successful crystal formation (Gether and Kobilka 1998).
Though a high–resolution structure for the inactive state of rhodopsin has
been available since 2000 (Palczewski et al. 2000), structures of the active
conformations of GPCRs and inactive conformations of GPCRs other than
rhodopsin are still unknown, and unfortunately no other GPCRs have been
crystallized since then.  As a result of these impediments in detailed
structural information on GPCRs, the majority of laboratories have focused
on indirect approaches, while still attempting to purify GPCRs of the
rhodopsin family and other families, and trying to obtain crystals
corresponding to activated states of these GPCRs.
Among the many indirect approaches, perhaps the most common one
has been homology modeling of the whole or specific regions of the GPCR of
interest using the rhodopsin structure as the prototypic template to predict
possible contact sites between helical transmembrane domains.  Conserved
residues between rhodopsin and other GPCRs, when available, have also been
invaluable in predicting possible interaction sites.  When a specific
interaction could not be easily conjectured, the relative orientation of
helices with one another based on the rhodopsin structure was used as a
guide to engineer pairs of His or Cys residues on each helical domain thought
to be in proximity with one another.  His residues that were closer were
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then determined by using their ability to coordinate with Zn2+ (Elling and
Schwartz 1996; Thirstrup et al. 1996), while the formation of a disulfide
bond between two Cys residues was indicative of close proximity between
the two Cys residues (Yu et al. 1995; Farrens et al. 1996; Zeng et al. 1999).
Indirect approaches used to predict environments of helices have
been very valuable in the correct orientation of helices with respect to each
other.  One of the more commonly used approaches for this has taken
advantage of systematic substitutions of the transmembrane domains with
Cys residues and subsequent determination of accessibility of these Cys
residues to solvent accessible probes.  The choice of probe in these studies
was either a membrane impermeable sulfhydryl–specific methane
thiosulfonate (MTS) reagent (Javitch et al. 1998; Altenbach et al. 1999)
where accessibility of the Cys residues to the MTS reagent is assessed in
substituted Cys accessibility method (SCAM), or a solvent accessible
paramagnetic probe where, after labeling of the Cys residues with a
sulfhydryl-specific nitroxide spin label, collision of this spin label with the
solvent accessible paramagnetic probe is assessed (Javitch et al. 1998;
Altenbach et al. 1999).
Collectively, all the above indirect studies helped define the proximity
and relative orientation of the helical domains with each other.  This in turn
allowed orientation of helical wheels to place possible interacting residues
nearby, thereby providing further insights into additional interaction
partners that can be experimentally ascertained, and new models that can be
developed and subsequently tested.
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In the case of Ste2p, the GPCR for the pheromone acting on S.
cerevisiae MATa cells, very few residues have been subjected to direct
interaction studies due partly to the absence in Ste2p of several conserved
motifs found in rhodopsin and other GPCR families.  In one of the earlier
studies (Sommers and Dumont 1997), random mutations were introduced into
the region of the STE2 gene encoding the third transmembrane domain
(TM3) of Ste2p, and a screen for mutants with reduced signaling was
performed.  The thus identified ste2– mutants were then subjected to a
second round of mutagenesis to screen for intragenic second–site
suppressors of the initial mutations that now conferred gain of Ste2p
function.  These screens allowed identification of three second–site
suppressors Y266C (TM6), M218T (TM5) and R58G (TM1) that were
stabilizers of the TM3 ste2– mutants.  Among these, possible interactions
between R58 (TM1) and E143 (TM3) were tested and no evidence of ionic
interactions was found between them.  However, Y266C (TM6) was
suggested to suppress the defective phenotype of E143K (TM3) only at very
high concentrations of a–factor in FUS1–lacZ reporter gene induction
assays, although no mating was observed in this double mutant
(Y266C/E143K).
Other than the above genetic analyses, possible intramolecular
interactions in Ste2p were proposed between Q253 (TM6) and either or
both of S288 (TM7; Dube and Konopka 1998) and S292 (TM7), and between
N84 (TM2) and Q149 (TM3; Parrish et al. 2002).  These interactions were
suggested based on the elimination of the ligand–independent constitutive
active phenotypes obtained in single mutations at each position upon creation
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of simultaneous double mutations at both of the putative interacting
positions.  Though no experiments were done to show direct interactions
between the suggested residues in the former study (Dube and Konopka
1998), the latter study (Parrish et al. 2002) attempted to test direct
interactions between N84 and Q149 by using reciprocal and swap mutations
on N84 and Q149.  Based on rescue of the previously observed single mutant
phenotypes in the double swap mutant (N84Q/Q149N), the presence of
possible interactions between N84 and Q149, the authors concluded, was
strengthened.  Finally, in yet another study, direct intramolecular
interactions in Ste2p were identified between V223 (TM5) and L247 (TM6)
when Cys substitutions at each of these two positions led to the formation
of a reversible disulfide bond between them (Dube et al. 2000).
In this part of the dissertation, we present systematic studies that
probe possible intramolecular interactions between several transmembrane
(TM) residues of Ste2p.  More specifically, we present data from studies
aimed at testing the existence of direct interactions between R58 (TM1)
and D275 (TM7) —with possible stabilization from Q135 (TM3), and
between E143 (TM3) and K225 (TM5) —with possible stabilization from
Q253 (TM6).  Our point of departure in testing these interactions was the
de novo models that were generated for the transmembrane region of
Ste2p, which implicated the above residues in forming partnering
interactions in the final 3–D structure (Figure 20).  The 3–D de novo models
generated in collaboration with Dr. Gregory Nikiforovich of Washington
University, St Louis, MO, for the transmembrane region of Ste2p represent
the first of its kind.  In this computer modeling Dr. Nikiforovich used only
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Figure 20.  Representation of One of the Deduced 3–D Models for the
Transmembrane Region of Ste2p.  Helices are shown as ribbons and side
chains for residues pertinent to discussion in text are shown as space–filled
models with color codes for residues corresponding to those for the side
chains.  The proposed interactions tested in this study are those between
R58 (TM1) and D275 (TM7) —with possible stabilization from Q135 (TM3),
and those between E143 (TM3) and K225 (TM5) —with possible stabilization
from Q253 (TM6).  This model was generated via de novo computer modeling
by Dr. Gregory Nikiforovich of Washington University, St Louis, MO.
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one structural experimental constraint, namely, that of the disulfide bond
linkage formed between the residues V223 (TM5) and L247 (TM6) as
determined previously by (Dube et al. 2000).
Despite the common practice of using homology modeling to rhodopsin
in the modeling of Ste2p, we have chosen to use predictions from the de
novo modeling approaches for Ste2p in guiding the direction of our
experiments.  This strategy was followed in keeping with the observation
that Ste2p is a distinct family of GPCR.  Therefore, structural differences
between rhodopsin and Ste2p, or for that matter any other GPCR that
belongs to a family other than rhodopsin, would only be a logical anticipation
of this inference.  Considering that rhodopsin has a covalently attached
ligand, which keeps the ligand binding site rather rigid, and all other GPCRs
known to date transduce binding of an external ligand into
activation/initiation of signal transduction, this conjecture in fact does not
appear to be too unreasonable for other GPCRs and even those from the
rhodopsin family.  Our contention is that the de novo models used here will
form the basis for a reliable framework within which the structure and
molecular function of Ste2p can further be explored, such as the one
presented here in this part of the dissertation.
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CHAPTER II.  RESULTS
De Novo Models Generated for the Transmembrane Region of
Ste2p–  The computational approach used to generate the de novo models
for the transmembrane region of Ste2p followed that outlined previously
(Nikiforovich and Marshall 2003).  In the proposed de novo model (e.g.
Figure 20), a complex interaction was observed among polar transmembrane
residues of Ste2p between side chains of R58 (TM1), D275 (TM7) and Q135
(TM3).  However, this interaction was not strongly pronounced since the salt
bridge between the guanidino group of R58 and the b–carboxyl of D275 was
possible only for certain rotamers, and hydrogen bonding between the
guanidino group of R58 and the g–carbonyl of Q135 did not occur in all
models.  On the other hand, the most specific feature of all proposed 3–D
models was the possibility for the salt bridge between the e–amino group of
K225 (TM5) and one of the oxygen atoms of the b–carboxyl of E143 (TM3).
According to the calculations used for the generation of the de novo models,
this interaction was very important for stabilization of the entire TM bundle
of Ste2p, and it could therefore serve to limit rotational possibilities of
TM3 and TM5.  In many instances, the e–amino group of K225 (TM5) was also
involved in hydrogen bonding with the g–carbonyl of Q253 (TM6).  Thus, the
salt bridge K225–E143 is not the only stabilizing element of the
TM3–TM5–TM6 triplet.  Additionally, in some structures hydrogen bonding
between the g–amino group of Q253 (TM6) and the other oxygen of the
b–carboxyl of E143 (TM3) was also observed.  Therefore, it may be more
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appropriate to characterize the polar stabilization discussed here as a
ternary interaction involving a salt bridge between E143 and K225, and
additional possibilities for hydrogen bonding between E143 and Q253,
and/or K225 and Q253.
Testing of Proposed Interactions Between Polar Groups in the
Transmembrane Region of Ste2p–  In order to test possible interactions
between the proposed polar transmembrane residues of Ste2p site–directed
mutagenesis was used.  The mutants were generated in the previously
described Cys–less Ste2p.FT.HT construct (see Parts III and IV of this
dissertation; also see Akal-Strader et al. 2002), which contained C–terminal
FLAG™ and His6 epitope tags, and had both of its native Cys residues
converted to Ser with no affect on the binding and biological activity of the
receptor.  The mutagenesis approach used in testing of the specific
interactions between transmembrane polar residues of Ste2p included a
combination of single, double and triple mutations at these positions.  The
thus generated mutant receptors were subsequently analyzed for their
biological activities as a means of assessing possible interactions between
the proposed residues (please see below).
Biolological Activities of Site–directed Mutants Generated to Test
for Interactions between R58 and D275–  In the calculated 3–D models of
Ste2p, potential salt–bridge interactions were noted between the residues
R58 (TM1) and D275 (TM7).  To test this prediction, site-directed
mutagenesis was performed that accommodated several single and double
mutations at these positions, as well as single and triple mutations including
position Q135 which, according to the de novo models, could also contribute
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stabilizing interactions through hydrogen bonding with the side chains of
R58 and D275.  If there were interactions between these two residues and
these interactions were important for the receptor function, then individual
single mutations, we reasoned, would result in a receptor with compromised
function.  Following this argument, we would also expect to see a full
recovery of the receptor function upon switching the residues at positions
R58 and D275 simultaneously.  In line with this thinking, R58 was replaced
by Ala, Asp, Glu, and Gln, and D275 was replaced by Ala and Arg.  In
addition, various mutant combinations were also performed to accommodate
R58/D275 double mutants and a triple mutant involving Q135 (Table 14).
Replacement of R58 by Ala, Asp, Glu, or Gln led to mutants showing
biological activities of 41–68%.  Replacement of D275 by Ala or Arg induced
Table 14.  Biological Activities of Ste2p Mutants Generated to
Test for Interactions Between R58 (TM1) and D275 (TM7)
Results are expressed as mean ± SE of at least two independent experiments performed in triplicate
Receptora % Maximal Inductionb
WT (Cys–less) 100 ± 4
R58A 68 ± 2
R58D 52 ± 1
R58E 61 ± 2
R58Q 41 ± 1
D275A 45 ± 1
D275R 33 ± 5
R58A/D275A 47 ± 4
R58D/D275R 46 ± 2
R58E/D275R 75 ± 2
Q135E 66 ± 3
R58Q/Q135E/D275R 85 ± 4
a Mutations were generated in the Cys–less Ste2p.FT.HT receptor background, which served as the
wild–type (WT) receptor.
b Biological activity was measured by the FUS1–lacZ reporter gene induction assay, and mutant
activities were compared with the Cys–less receptor.
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a somewhat larger loss of biological activity in the range of 33–45%.  These
results suggested that R58 and D275 were individually important, but not
essential, for the activity of the receptor.  Consistent with this conclusion,
the double mutant R58A/D275A, where both charges were eliminated by
substitution with Ala, resulted in a receptor with a low level of biological
activity (47%) similar to that of the single mutant receptors.  In order to
assess the existence of an interaction between positions R58 and D275, the
switch mutant R58D/D275R was generated where the charged groups of
potential partners were swapped.  The biological activity of this mutant
receptor, however, did not improve from what was observed for the double
mutant R58A/D275A.  On the other hand, a second switch mutant
R58E/D275R, in which R58 was replaced by a conservative substitution for
Asp to give a longer side chain, exhibited 75% of the biological activity of
the wild–type receptor.  Taken together, these results suggested that
direct interactions between R58 and D275 could exist but these
interactions were not crucial for stabilization of the 3–D structure of
Ste2p.  However, the possibility that these residues were also stabilized by
interactions with other polar or ionic groups could not be ruled out.  In this
regard, the proposed Ste2p model indicated a potential three–way
interaction among residues R58, Q135, and D275.  To assess contribution of
Q135 in the stabilization of the putative interaction between R58 and D275,
the circular triple mutant R58Q/Q135E/D275R was generated.  This mutant
restored the function of the receptor to 85% of that of the wild–type
receptor.  In comparison, mutants with only one mutation, namely R58Q,
Q135E, and D275R, had activities of 41%, 66%, and 33%, respectively.  This
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result was consistent with the conclusion that the three residues R58,
Q135, and D275 were interacting in Ste2p.
Biolological Activities of Site–directed Mutants Generated to Test
for Interactions between E143 and K225–  In the calculated 3–D models
of Ste2p, potential salt-bridges and/or ionic interactions were also noted
between E143 (TM3) and K225 (TM6).  To test this prediction, site-directed
mutagenesis was performed that accommodated several single and double
mutations at these positions.  If there were interactions between these two
residues and these interactions were important for the receptor function,
we speculated that individual single mutations would result in a receptor with
compromised function in a manner similar to those observed above in
R58–D275 interaction studies.  Similarly, we would also expect to see a full
recovery of the receptor function upon simultaneous switching of the
residues at positions 143 and 225.  Using similar approaches as those
described in studies aimed at determining the interaction between R58 and
D275, E143 was replaced by Ala and Lys, and K225 was replaced by Ala and
Glu (Table 15).
Individual single and double mutations at positions E143 and K225
were highly deleterious to the receptor function, with E143A, K225A, and
K225E retaining about 30–40% of their biological activity, and
E143A/K225A and E143K/K225E showing no activity in the FUS1–lacZ
reporter gene induction assays.  Expression studies revealed that the
biologically inactive receptors E143K, E143A/K225A, and E143K/K225E were
not expressed as determined by immunoblots of total membranes prepared
from yeast extracts (Figure 21).  These results suggested that the two
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Table 15.  Biological Activities of Ste2p Mutants Generated to
Test for Interactions Between E143 (TM3) and K225 (TM5)
Results are expressed as mean ± SE of at least two independent experiments performed in triplicate
Receptora % Maximal Inductionb
WT (Cys–less) 100 ± 4
E143A 36 ± 6
E143K NEc
K225A 32 ± 3
K225E 41 ± 4
E143A/K225A NEc
E143K/K225E NEc
a Mutations were generated in the Cys–less Ste2p.FT.HT receptor background, which served as the
wild–type (WT) receptor.
b Biological activity was measured by the FUS1–lacZ reporter gene induction assay, and mutant
activities were compared with the Cys–less receptor.
c NE= Not Expressed.  These receptors were not expressed as measured by immunoblot of total
membranes.
Figure 21.  Western Blot Analysis of E143K, E143A/K225A and
E143K/K225E Mutant Receptors.  Total membranes were prepared as
described in Experimental Procedures (Part II).  10% SDS–PAGE gel was
loaded with 25 mg total membrane proteins and western blot analysis was
performed as described in Part II using FLAG™ antibody.
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residues E143 and K225 were also not essential for the receptor function
since E143A and K225A retained about 35% of their biological activity.  On
the other hand, the lack of expression of receptors carrying certain
mutations could indicate that interaction between E143 and K225 may be
involved in stabilizing the receptor during folding and maturation.  The de
novo models generated for Ste2p suggested that Q253 could also
participate in the stabilization of a possible interaction between E143 and
K225 through hydrogen bonding interactions with E143 or K225.  However,
this possibility was not explored any further due to deleterious effects of
several mutations involving residues E143 and K225 that were caused by lack
of expression of these mutants.
111
CHAPTER III.  DISCUSSION
Previous 3–D models for the yeast S. cerevisiae GPCR Ste2p were
derived from the combination of site–directed mutagenesis and direct
interaction data with the homology modeling to rhodopsin (Dube and Konopka
1998; Parrish et al. 2002).  Rhodopsin contains a tethered ligand, which
separates it from all other GPCRs that use binding of an external ligand to
propagate the signal.  Yet, rhodopsin has been used extensively as a
prototype model in structure interpretation of both rhodopsin and
non–rhodopsin families of GPCRs due to representing the only high–resolution
structure of a GPCR to be determined to date (Palczewski et al. 2000).
Owing to distinct differences anticipated between rhodopsin–like and
non–rhodopsin–like GPCRs, we have sought to use an alternative approach to
determining the 3–D structure of Ste2p.  A combination of statistical
analysis with energy minimization (Nikiforovich and Marshall 2003) led to
identification of several low energy conformations and hence generation of
the first de novo models for the 3–D structure of the transmembrane region
of Ste2p.  The 3–D models suggested by our de novo modeling approach is
compatible with most of the available experimental data on Ste2p that is
interpretable in structural terms.  Observations made in these models
regarding specific polar residue interactions in Ste2p concurrently provided
the basis for the experimental strategies followed in this part of the
dissertation that allowed testing of these models.
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The de novo models generated for the transmembrane region of
Ste2p predicted several polar residues to be involved in a complex network
of interactions.  An ionic interaction that was noted in several of the de novo
models was proposed between R58 and D275, while a possible hydrogen
bonding interaction from Q135 also appeared to stabilize this interaction.  A
second ionic interaction was proposed to be between E143 and K225, and it
was suggested to play a very crucial role in the stabilization of the
transmembrane bundle of Ste2p receptor due to the observation of this
interaction in all of the de novo models.  This ionic interaction appeared to
be a complex one as well in that hydrogen bonding interactions between E143
and Q253, and/or K225 and Q253 were observed to also stabilize this
interaction.
In efforts to determine possible existing interactions between R58
and D275, and E143 and K225, not excluding the possible respective
contributions from Q135 and Q253, several site–directed mutants were
generated at these positions (Tables 14 and 15).  In these studies R58 was
replaced by Ala, Asp, Glu, and Gln; D275 by Ala and Arg; Q135 by Glu; E143
by Ala and Lys; and K225 by Ala and Glu.  In addition, several of these single
mutations were also combined in double and triple mutant receptors.
Single mutations at positions R58 and D275 pointed to the important
but non–essential role of these two residues in the biological activity of the
receptor.  Evidence for possible interactions between these two residues
came from several lines of observations.  For instance, single mutants of R58
and D275 displayed non–additive phenotypes when combined in the double
mutants, as judged by the biological activity measurements (compare R58A
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(68%), D275A (45%), R58D (52%), and D275R (33%) with R58A/D275A
(47%) and R58D/D275R (46%) in Table 14).  In addition, the switch mutant
R58E/D275R restored 75% of the wild–type activity, which was an improved
activity compared to the single mutants R58E (61%) and D275R (33%) and
the double switch mutant R58D/D275R (46%).  Finally, the circular triple
mutant R58Q/Q135E/D275R, created to explore contributions from Q135
to R58–D275 interaction, displayed 85% of the wild–type activity.  This
corresponded to an additional 10% improvement in the activity of the triple
mutant when compared with the double mutant R58E/D275R (75%).
Commensurate with these experimental findings, notwithstanding the lack of
complete restoration of receptor activity, we concluded that an interaction
between R58 and D275 existed, and that this interaction was stabilized
further by the triangulate hydrogen bonding interactions from Q135.
Single mutations at positions E143 and K225 resulted in biological
activities that were more dramatically reduced than those observed in
studies with R58 and D275 (Table 15).  E143A, K225A, and K225E mutants
displayed 30–40% biological activities, while E143K completely lost its
activity.  Loss of biological activity of E143K was attributed to its lack of
expression as determined by western blot analysis of total membranes from
yeast extracts of E143K (data not known).  Presence of direct interaction
between E143 and K225 could not be ascertained because both the
E143A/K225A and E143K/K225E double mutant receptors displayed no
biological activity, which was also as a result of lack of their expression in
western blot analysis (data not shown).
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Detailed analysis and studies on membrane proteins have established
that insertion of the transmembrane domains of membrane proteins follows
certain signals.  These vectorial signals are distributed along the sequence
of the membrane proteins; however, transmembrane orientation and topology
are not determined solely by the vectoriality of insertion of the first
transmembrane segment, followed blindly by insertion in alternating
orientations of the hydrophobic segments downstream (Ehrmann and
Beckwith 1991; Kaback 1992).  Vectoriality is primarily determined by the
distribution of charged residues in the vicinity of the ends of the helices
(Whitley et al. 1993) and genetic manipulation of the distribution of charged
residues can cause transmembrane segments to insert with inverted
vectoriality (von Heijne et al. 1988; Yamane et al. 1990; Ehrmann and
Beckwith 1991; McGovern et al. 1991).  Based on these observations, one
might think that our manipulations with E143 and K225 could result in the
observed expression problems in most mutant receptors at these positions.
However, this is probably not the case since both E143A and K225E mutants
were expressed and displayed above zero biological activities (36% and 41%,
respectively).
Despite the lack of biological data on E143/K225 double mutant
receptors as a consequence of problems in expression of these mutants, it is
still premature to conclude that ionic interactions between E143 and K225
do not exist.  One would expect that the existing interactions between E143
and K225 that were lost with single mutations at these positions would be
restored in the switch mutant E143K/K225E.  However, it is reasonable to
think that the microenvironments of these residues in their respective
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transmembrane domains may be dramatically altered upon switching of the
charges such that even existing salt bridge interactions could not restore a
functional receptor.  It is also likely that a third residue, such as Q253 that
was proposed in our de novo models, could be poised correctly to stabilize
the E143–K225 interaction, and it could do so only if the charged groups
were in their native positions, but not when they were switched.  This was a
possibility that was not tested in our studies.  Expression problems with
most mutations on E143 and double mutants involving E143 and K225
discouraged us from pursuing this line of mutagenesis studies.  Regardless,
our studies with E143 and K225 suggested that residue E143 and its possible
interaction with K225 may be involved in stabilization of the receptor for
proper folding and maturation.
In membrane proteins the hydrophobic region of the lipid bilayer
provides a very distinctive region of solvation.  Due to absence of the
hydrophobic effect, ionic interactions usually tend to be strong over long
distances in the low dielectric environment of the membrane lipid.  For
example, in the LHC–II (eukaryotic light–harvesting complex), polar groups
are buried as ion pairs involved in prosthetic group binding and ion pairing
greatly facilitates the insertion of charges into the membrane (Kuhlbrandt
et al. 1994).  Though helix–helix association could be facilitated by single,
strongly polar interactions, such as interhelical hydrogen bonds, bridging
water molecules, or ion pairs, strong hydrogen bonds or ion pairs may also
create a danger of nonspecific aggregation or misfolding (Popot and
Engelman 2000).  An intriguing possibility is that strong, local interactions
are not favored for biological reasons, such as protein turnover and/or
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function.  The danger presented by the strength of hydrogen bonds or ion
pairs between helices is that they can overwhelm all other interactions,
potentially leading to nonspecific aggregation or misfolding.  In this regard,
it is likely that in Ste2p a weak ionic interaction could exist between E143
and K225.  On the other hand, this interaction could be rendered stronger
than before as a result of the simultaneous reciprocal mutation in our
E143K/K225E switch mutant.  Such a scenario could account for the
observed expression problems with most mutations on E143 and K225, but
more importantly, it could explain why the E143A/K225A double mutant was
not expressed when the individual single mutants E143A and K225A were
expressed.
Some of the mutations generated in our studies with R58–D275 and
E143–K225 interactions were also previously identified and/or studied in
other mutagenesis or phenotypic screens.  Comparison of the data obtained
from our rationally designed Ste2p mutants with those available from the
literature on Ste2p point to some differences in terms of residue contact
sites.  For instance, based on the observation that each of the mutants
Q253L, S288A and S292A showed strong constitutive activity, which was
eliminated in the double mutants formed by mutations at these positions,
Q253 was suggested to be in contact with S288 and/or S292 (Dube and
Konopka 1998).  However, the possibility of a direct interaction between
these residues was not tested via mutagenesis approaches in this or other
studies.  In another study, a specific interaction between E143 and Y266
was proposed based on the observation that Y266C mutation restored loss
of Ste2p function caused by E143 mutation in gene induction assays
117
(Sommers and Dumont 1997).  The authors, however, noted that the
E143K/Y266C mutant receptor was unable to mate and that the observed
recovery of the receptor function corresponded only to very low efficacies
of a–factor.  To explore the possibility that Y266C mutation could suppress
the E143K mutation in our hands, we generated the double mutant receptor
E143K/Y266C.  Gene induction assays on this mutant receptor in two
different non–isogenic yeast strains suggested that Y266C could not
suppress the null phenotype of E143K mutation (data not shown).  This
observation provided supporting evidence for a possible interaction between
E143 and another residue, such as K225.  The same study (Sommers and
Dumont 1997) also predicted an interaction between R58 and E143.
Interestingly, however, mutagenic studies specifically aimed at elucidating
this interaction concluded that no evidence existed for an ionic interaction
between R58 and E143, thereby leaving the two residues free to interact
with other partnering residues, such as D275 and K225, respectively.
To sum up, results from mutagenesis studies on E143 and K225 were
somewhat inconclusive due to lack of expression by many mutants
constructed at these positions.  Nonetheless, the possibility of an ionic
interaction between E143 and K225 could not be overruled, considering that
these residues contain charged groups that are embedded in the lipidic
environment, and that E143 and its proposed interactions with K225 appear
to play an important role in maintaining the correct fold and structural
integrity of the receptor.  On the other hand, results from studies with
R58, D275, and Q135 supported a possible triangulate interaction between
them in keeping with the observation that 85% of the biological activity of
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the receptor was restored in the triple mutant R58Q/Q135E/D275R.  A
skeptical reader could raise a number of challenges to the conclusions just
drawn in light of the observation that none of the double or triple mutations
on R58, D275 and Q135 were able to restore a fully functional receptor, and
that a clear evidence for an interaction between E143 and K225 could not be
presented.  Though these are valid arguments, the mutational studies rarely
present straightforward results. Furthermore, the positions of the
interacting residues in the protein may also dictate the nature of
interactions between them.  Our models predict that R58, D275, and Q135
are closer to the extracellular surface while E143 and K225 are deeply
buried in the membrane.  That D275 is about 85% accessible to a
hydropholic sulfhydryl reagent (Lin et al. 2003) supports its location close to
the extracellular milieu.  The relative contribution of solvent exposed ionic
interactions to the overall stability of the protein may be compensated in
part by solvent hydration and other available charged groups on the protein
surface or the surface of the membrane (Hendsch and Tidor 1994; Hendsch
et al. 1996; Makhatadze et al. 2003).  In contrast, ionic interactions that are
buried within the hydrophobic protein core maybe more crucial to the overall
stability of the protein (Kumar and Nussinov 1999).  Notably, in our de novo
models possible interaction between E143 and K225 was proposed to play a
vital role in the stabilization of the transmembrane bundle of Ste2p.
Observation of this interaction in all the generated de novo models further
highlighted the importance of the interaction between E143 and K225.  The
interaction between R58 and D275, in contrast, was observed in most but
not all de novo models, suggesting other alternative interactions for R58 and
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D275.  To continue with a more speculative note, the mutant receptor R58G
was identified in a previous study to act as a second–site suppressor of the
nonfunctional mutant receptors isolated from random mutagenesis of the
third transmembrane domain (TM3) of Ste2p (Sommers and Dumont 1997).
Interestingly, this suppression was not in an allele–specific manner; rather,
R58G was found to play a role as a global stabilizer of several mutants from
TM3.  This observation could be interpreted in terms of possible
interactions of R58 with multiple regions of the receptor, since a direct
interaction between R58 and the residues of TM3 that upon mutation
resulted in non–functional receptors could not be found.  These results could
also account for the observation that R58–D275 interaction was identified
only in some low energy conformations in our de novo models, and that
contributions from other residues, such as Q135, could complement the full
function of the receptor in the R58–D275 interaction.
In the case of Ste2p, evidence for a direct interaction between two
residues was regarded more convincing if single mutations at the two residue
positions caused an interesting phenotype, which disappeared upon
simultaneous double mutations at the same two residues.  An example for
such a situation was seen between N84 in TM2 and Q149 in TM3 (Parrish et
al. 2002), where amino acid substitutions at both positions resulted in
constitutive activity, which could be eliminated by double mutations at these
positions.  Interestingly, most mutations at these positions that caused
constitutive activity resulted in wild–type like receptor activity in the
presence of saturating amounts of a–factor.  Despite the absence of an
interesting phenotype in the presence of a–factor, the above observations
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suggested an interaction between N84 and Q149 based on alterations in
their basal activity, which in turn suggested that these residues were
involved in the stabilization of the receptor in the inactive state.  In efforts
to strengthen our argument for the existence of possible interactions
between R58 and D275, and E143 and K225, and/or determine roles of these
residues in the stabilization of the inactive state of Ste2p, we looked at the
ligand–independent activation (basal activity) of all of our mutant receptors
in FUS1–lacZ gene induction assays.  However, none of the mutants that
were expressed displayed basal activities in the absence of a–factor that
were greater than that of the wild–type receptor (data not shown).  Since
we were unable to observe constitutive activity by our mutants, we surmised
that none of these residues were involved in stabilization of the inactive
state of the receptor.  On the other hand, the interesting phenotypes in
terms of maximal activation obtained in several of our single and multiple
mutants still provided tantalizing evidence for the presence of the
previously suggested interactions between R58, D275 and Q135, and
between E143 and K225.
In conclusion, our de novo models, which are partly validated by our
aforementioned studies, agree with most of the mutagenesis data available
for Ste2p.  This is encouraging in that further validation of our models for
the transmembrane region of Ste2p could allow accurate incorporation of
the N– and C–termini as well as the connecting loops of the receptor to yield
a more complete 3–D structural information for Ste2p.  Our contention is
that the de novo models generated for Ste2p will serve as a good framework
121
to test additional interactions and provide further insights into various
activated states of Ste2p.
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PART VI.  CONCLUSIONS
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CHAPTER I.  SUMMARY AND IDEAS FOR FUTURE STUDIES
In the studies presented in this dissertation, we used the
Saccharomyces cerevisiae pheromone, a–factor (WHWLQLKPGQPMY), and
Ste2p, its G protein–coupled receptor, as a model system to study
ligand–receptor interaction.  Cys–scanning mutagenesis on each residue of
EL1, the first extracellular loop of Ste2p, allowed us to generate a library of
36 mutants with a single Cys residue substitution.  Mutation of most
residues of EL1 had only negligible effect on ligand affinity and biological
activity of the mutant receptors.  However, we identified five mutants that
were either partially (L102C and T114C) or severely (N105C, S108C and
Y111C) compromised in signaling but retained binding affinities similar to
those of the wild–type receptor.  Ala–scanning mutagenesis studies of the
residues from 102 through 114 gave similar results, thereby further pointing
to the importance of this region of EL1 in the activation of the
receptor–mediated signal transduction pathway.  3–D modeling, secondary
structure predictions, and subsequent circular dichroism studies on a
synthetic peptide with amino acid sequence corresponding to EL1 suggested
the presence of a helix corresponding to EL1 residues 106 to 114 followed by
two short b–strands corresponding to residues 126 to 135.  The distinctive
periodicity of the five residues with a signal–deficient phenotype combined
with biophysical studies suggested a functional involvement in receptor
activation of a face on a 310–helix in this region of EL1.  These studies
indicate that EL1 plays an important role in the conformational switch that
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activates the Ste2p receptor to initiate the mating pheromone signal
transduction pathway.
Similar approaches as those used in studies with EL1 were also applied
to the third extracellular loop (EL3) of Ste2p for the structure and function
relationship determination of this loop.  In this way, a library of 15
additional mutant receptors with single Cys substitution was generated.
Through these studies two other mutants with signal–deficient phenotypes
were identified.  Among these, Y266C displayed no detectable activity while
G273C displayed partial activity.  Results from these studies implicate the
importance of specific residues of this loop in the activation of the
receptor–mediated signal transduction pathway.
Cys–scanning mutagenesis of EL1 and EL3 of Ste2p, collectively,
highlighted the important role these loop residues played in the activation of
the Ste2p receptor.  Specific mutations on these loops prevented the
receptor from performing its biological function.  This was most likely due to
the role these residues played in stabilizing Ste2p in its inactive state by
their inability to interact with the correct residues after being mutated.
Subsequently, the inability of Ste2p in changing its conformation proved to
be indispensable for a fully functional receptor conformation to be attained.
We wanted to determine if the inactive conformations of these mutant
receptors could be overcome by a mutation that could stabilize Ste2p in a
more active state.  To address this point, we incorporated a constitutively
activating mutation (P258L) into each of the single Cys substituted EL1 and
EL3 signal–deficient receptor mutants.  In this way, several doubly
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substituted receptor mutants were generated, where one of the mutations
was the P258L substitution and the other mutation was a single Cys
substitution of EL1 or EL3 that previously resulted in a signal–deficient
phenotype.  We subjected these double receptor mutants to further studies
aimed at determining their ability to display constitutive activity in the
absence and presence of a–factor.  Results from these studies indicated
that in the absence of the pheromone ligand a–factor, each of these double
mutant receptors displayed elevated basal activities when compared to the
those observed in the single Cys substituted mutants prior to the addition of
the constitutively activating mutation.  Furthermore, while P258L was fully
activated in the presence of saturating amounts of a–factor, the double
receptor mutants were not activated fully under the same conditions.
Results from these studies suggested that even a strong activating
mutation, such as P258L, was unable to shift the conformations of these
mutant receptors to a fully active state.  Nevertheless, the double
receptors were in a somewhat more activated state as judged by their
ability to display elevated basal activities in the absence of the ligand.
These observations further corroborate the previously noted importance of
the first and third extracellular loops, EL1 and EL3 of Ste2p, pointing to the
significance of the structural integrity of these loops for the full activation
of the receptor.  These results also hint at the presence of intermediate
conformational states for the double receptor mutants, which precede that
attained by the P258L mutant receptor, thereby implicating a possible
multi–step activation process for Ste2p.
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Crystal structure determination of GPCRs has proven unsuccessful due
to their hydrophobic nature, and due to problems associated with
solubilization of membrane proteins for successful crystalization.  The only
exception to this has been the light–adapted rhodopsin for which a
high–resolution structure in the resting state has been determined
(Palczewski et al. 2000).  As a result, homology modeling to rhodopsin, rather
than crystallization, has been utilized in the structure determination of
other GPCRs.  Since refining a 3–D model requires the availability of as many
constraints as possible, information gleaned from different conformational
states attained by various classes of mutants can be very useful in building
an accurate model for the 3–D structure of any GPCR including Ste2p.
Our studies with single Cys–scanned EL1 and EL3 mutants, as well as
the double receptor mutants generated by incorporating the constitutively
activating mutation (P258L) into each Cys–scanned signal–deficient EL1 and
EL3 mutant, suggested that these receptors could attain varying
conformations between the inactive and fully active states.  Knowledge of
different conformations attained by each of these mutant receptors would
be very valuable in building 3–D models for Ste2p.  One way of determining
conformations of these mutants is to use the substituted Cys accessibility
method (SCAM).  The premise of this method is to replace each residue of
interest by Cys and then assess the accessibility of this Cys residue to a
sulfhydryl–specific reagent, such as methane thiosulfonate ethanolamine
biotin (MTSEA–Biotin).  This approach has previously been used in single Cys
containing Ste2p mutants where environments of residues located on the
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sixth and seventh transmembrane domains (TM6 and TM7) of Ste2p were
determined successfully (Lin et al. 2003).  In these studies mutant receptor
T199C was found to be the most accessible of all mutants studied while the
mutant receptor Y266C was found to be inaccessible.  These mutants can
serve as good controls in assessing relative accessibilities of our single Cys
containing mutant receptors from EL1 and EL3 both in the presence and
absence of the P258L mutation.  With this prospect, we have initiated
studies with the control mutant receptors T199C and Y266C and assessed
their accessibility to MTSEA–Biotin.  Results from these preliminary
experiments have been very promising; however, due to incompleteness of
these studies and lack of data on additional mutant receptors, these data
have not been included in this dissertation.  Further studies will therefore
need to be done to allow determination of the conformations attained by our
Cys–scanned EL1 mutant receptors, especially in the predicted 310–helical
region.  Similar studies should also allow determination of the various
conformations attained by the double mutant receptors containing the
P258L mutation.  Results from all these experiments should provide
constraints for models to be generated for the inactive, fully active as well
as the intermediate conformational states of Ste2p.  These models will in
turn be very informative in understanding the mechanism of activation
process of Ste2p and thus of other G protein–coupled receptors.
In addition to the SCAM approach that we have tried to develop for
our Ste2p mutants, the conformations of the single Cys substituted active
and signal–deficient receptors from EL1 and EL3, as well as the same
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mutants in the constitutively active P258L receptor background, could also
be determined by biophysical techniques.  In one approach, these receptors
can be labeled with a fluorescent group on their Cys residue.  The
environment of the fluorescent group on the specific regions of EL1 and EL3
with or without the P258L mutation can then be probed in the presence and
absence of a–factor.  A similar idea was used in a previous study albeit in a
reverse manner where the a–factor pheromone was fluorescently labeled
rather than the receptor itself (Ding et al. 2001).  In the second approach,
the same receptors can be spin labeled on their Cys residues and the ability
of the spin labeled Cys residues to collide with a solvent accessible
paramagnetic probe can be used to determine the environment of the
specific loop residues.  This approach has been successfully applied to other
GPCRs previously (see review by Gether 2000 and references therein).
Besides studies with the extracellular loop residues of Ste2p, several
other residues located in the membrane spanning regions of Ste2p became
the focus of our studies.  In several de novo models generated for the
transmembrane (TM) region of Ste2p certain residues were predicted to be
in close enough vicinity to one another to form interacting partners.  One of
these interactions was predicted to be between R58 (TM1) and D275 (TM7)
—with the possible involvement of Q135 (TM3), and the other interaction
was predicted to be between E143 (TM3) and K225 (TM5) —with the
possible involvement of Q253 (TM6).  In order to test the validity of these
models we generated several single, double and triple mutant receptors at
these residues.  Our studies with the first set of interactions showed that a
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triple mutant (R58Q/Q135E/D275R) retained 85% of the wild-type
receptor activity, while individual single mutations at these positions
resulted in 25–75% reduced activities.  These observations suggested a
possible interaction between R58 and D275 that was most likely stabilized
by Q135.  Our studies with the second set of interactions were arguable due
to expression problems encountered in mutant receptors with substitutions
at the residue position E143.  While it was not possible to determine
interactions between E143 and K225, our results did not preclude the
possibility of existence of such an interaction between these two residues.
The lack of results from studies with E143 and K225 notwithstanding,
results obtained from the studies with R58, D275 and Q135 corroborated
predictions of the de novo models generated for Ste2p.
In conclusion, if we take an overview of the contributions made by the
work presented in this dissertation, the following assessments would be fair
to rationalize.  To begin with, our work has focused on regions of Ste2p that
were previously not investigated by other research groups working on the
same system.  Since a considerable portion of the receptor constituted the
subject of our studies and mutagenesis was the method of choice, the
investigations were done using scanning mutagenesis approach.  Combined
with the single–stranded DNA mutagenesis technique, Cys–scanning
mutagenesis alone provided a library of single Cys–substituted receptor
mutants for use in a variety of other applications, such as cross–linking and
specific labeling of the Cys residues.  Together, Cys– and Ala–scanning
mutagenesis allowed a fast and efficient way of generating and
characterizing our mutant receptors.
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The first example where single residues on the extracellular regions
of a GPCR were implicated in the activation of the receptor but not binding
of the ligand came from these studies.  Another interesting highlight of our
studies was the implication of a specific structure, such as 310–helix, by our
molecular biological and biochemical studies.  To our knowledge, this is the
first example where experimental results alluded to the presence of a
structure without previous knowledge of specific structural information.
Combining signal–deficient receptor mutants obtained from our
scanning mutagenesis studies with an active state stabilizing, constitutively
activating mutation allowed us to identify several intermediate
conformational states for Ste2p.  Our single Cys–substituted mutants with
or without additional mutations represent excellent targets for the SCAM
approach.  If conformations of each of the different states of Ste2p
mutants containing single Cys substitution can be assessed by this approach,
the results will be very useful in providing determinants for generation of
accurate the 3–D models of Ste2p in the inactive, partially active and fully
active states.
Finally, studies where we tested interactions between specific
residues predicted by the de novo models for the TM region of Ste2p
allowed partial validation of these models.  Not only do these models
represent the first de novo models to be generated for Ste2p, but also form
the basis for generation of the complete 3–D structure of Ste2p with the
incorporation of the connecting loops as well as the N– and C–termini.  These
models can then be refined further using the available mutagenesis and
accessibility data for the various activated states of Ste2p.
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Based on studies presented in this dissertation and observations made
therein, we propose a model to explain our thinking of how activation of
Ste2p may be controlled by residues of the first and third extracellular
loops, EL1 and EL3, of the receptor (Figure 22).  In this model arrangement
of the transmembrane helix bundle places the third transmembrane domain
(TM3) in the center of the receptor, and the overall arrangement of helices
in general agrees with the mutagenesis data on Ste2p.  Here the
extracellular and intracellular loops (ELs and ILs) are shown with their
connectivities to their respective TM regions on the receptor.  On the
extracellular side, TM2 and TM3 are connected by EL1, TM4 and TM5 by
EL2, and TM6 and TM7 by EL3.  On the intracellular side, TM1 and TM2 are
connected by IL1, TM3 and TM4 by IL2, and TM5 and TM6 by IL3.  The two
termini of the receptor are also shown, where N–terminus is connected to
TM1 on the extracellular side and C–terminus is connected to TM7 on the
intracellular side.
We rationalize that the important roles of the EL1 and EL3 residues
stem from their connectivity to TM3 and TM6, respectively, which were
formerly identified in other GPCRs to play crucial role in the activation of
the receptor (Gether 2000).  In previous studies, engineering of disulfide
bonds (Farrens et al. 1996), or metal ion binding sites (Sheikh et al. 1999)
between TM3 and TM6 prevented the receptor from activating its G protein.
Based on these studies it was proposed that, looking from the cytosolic side
of the receptor, a clockwise rotation of TM3 was required for a clockwise
rotation of TM6, which allowed movement of TM6 away from TM3 by about
10–15 Å.  Restraining these two TM domains by engineered disulfide or metal
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Figure 22.  Proposed Model for Activation of Ste2p.  Side view of Ste2p
is shown.  Transmembrane domains are labeled TM1–7; intracellular loops
(ILs) are labeled IL1–3 (gray dashed lines); extracellular loops (ELs) are
labeled EL1–3 (dashed lines; EL1 and EL3 in green, EL2 in gray); and
N–terminus and C–terminus are labeled N and C, respectively.  The ELs and
N–terminus are located on the extracellular region, while the ILs and
C–terminus are located on the cytosolic region.  EL1 connects TM2 to TM3;
EL2 connects TM4 to TM5; EL3 connects TM6 to TM7; IL1 connects TM1 to
TM2; IL2 connects TM3 to TM4; and IL3 connects TM5 to TM6.  A  Model
showing resting (inactive) state of the receptor.  B  Model showing activated
state of the receptor.  Rotation of TM3 and TM6 with respect to each other
(curved red arrows) results in movement of TM6 away from TM3 (straight
red arrow) thereby exposing critical residues in the cytoplasm to G protein.
Specific interactions of EL1 and EL3 residues with other regions of Ste2p
allow activation of the receptor.
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ion binding sites disallowed this movement and therefore prevented
activation of the G protein.
In an analogous way, in our model we are proposing that specific
interactions of residues of Ste2p EL1 and EL3 permit rotation of TM3 and
TM6 with respect to each other and thus lead to activation of the G protein
(Figure 22–B).  When interactions of EL1 and EL3 residues with their
contact sites are prevented by mutations, such as substitution with Cys,
receptor becomes unable to activate its G protein (Figure 22–A).
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